KR20210014231A - Composition for prevention or treatment of muscular disorders or improvement of muscular functions comprising seaweeds extract - Google Patents
Composition for prevention or treatment of muscular disorders or improvement of muscular functions comprising seaweeds extract Download PDFInfo
- Publication number
- KR20210014231A KR20210014231A KR1020190091417A KR20190091417A KR20210014231A KR 20210014231 A KR20210014231 A KR 20210014231A KR 1020190091417 A KR1020190091417 A KR 1020190091417A KR 20190091417 A KR20190091417 A KR 20190091417A KR 20210014231 A KR20210014231 A KR 20210014231A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- seaweed
- muscle
- sargassum
- gracilaria
- Prior art date
Links
- 241001474374 Blennius Species 0.000 title claims abstract description 122
- 239000000284 extract Substances 0.000 title claims abstract description 101
- 239000000203 mixture Substances 0.000 title claims abstract description 72
- 230000006870 function Effects 0.000 title abstract description 4
- 230000003387 muscular Effects 0.000 title abstract 3
- 208000021642 Muscular disease Diseases 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title description 11
- 230000006872 improvement Effects 0.000 title description 4
- 230000002265 prevention Effects 0.000 title description 2
- 235000013305 food Nutrition 0.000 claims abstract description 23
- 239000002537 cosmetic Substances 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims description 41
- 208000029578 Muscle disease Diseases 0.000 claims description 40
- 230000004220 muscle function Effects 0.000 claims description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 20
- 239000004480 active ingredient Substances 0.000 claims description 20
- 206010028289 Muscle atrophy Diseases 0.000 claims description 18
- 239000002904 solvent Substances 0.000 claims description 17
- 125000004432 carbon atom Chemical group C* 0.000 claims description 16
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- 201000000585 muscular atrophy Diseases 0.000 claims description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 12
- 239000003960 organic solvent Substances 0.000 claims description 12
- 239000012530 fluid Substances 0.000 claims description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 235000012434 pretzels Nutrition 0.000 claims description 9
- 241000195493 Cryptophyta Species 0.000 claims description 7
- 206010028372 Muscular weakness Diseases 0.000 claims description 7
- 201000006938 muscular dystrophy Diseases 0.000 claims description 7
- 206010006895 Cachexia Diseases 0.000 claims description 6
- 241000439005 Ecklonia stolonifera Species 0.000 claims description 6
- 230000036473 myasthenia Effects 0.000 claims description 6
- 208000001076 sarcopenia Diseases 0.000 claims description 6
- 241000242305 Codium contractum Species 0.000 claims description 5
- 241000196222 Codium fragile Species 0.000 claims description 5
- 241000199917 Costaria costata Species 0.000 claims description 5
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 5
- 241000243681 Eisenia bicyclis Species 0.000 claims description 5
- 241000142861 Gloiopeltis furcata Species 0.000 claims description 5
- 241000691324 Gloiopeltis tenax Species 0.000 claims description 5
- 241000703932 Gracilaria bursa-pastoris Species 0.000 claims description 5
- 241000703861 Gracilaria textorii Species 0.000 claims description 5
- 241000703939 Gracilariopsis longissima Species 0.000 claims description 5
- 241000248373 Grateloupia elliptica Species 0.000 claims description 5
- 241001507103 Hypnea japonica Species 0.000 claims description 5
- 241000631638 Ishige sinicola Species 0.000 claims description 5
- 244000184734 Pyrus japonica Species 0.000 claims description 5
- 241001260859 Sargassum confusum Species 0.000 claims description 5
- 241001260874 Sargassum horneri Species 0.000 claims description 5
- 241000506359 Sargassum sagamianum Species 0.000 claims description 5
- 241000593948 Sargassum serratifolium Species 0.000 claims description 5
- 241000593491 Sargassum siliquastrum Species 0.000 claims description 5
- 241000593522 Sargassum thunbergii Species 0.000 claims description 5
- 241001126856 Scytosiphon lomentaria Species 0.000 claims description 5
- 241000196259 Ulva pertusa Species 0.000 claims description 5
- 241001261505 Undaria Species 0.000 claims description 5
- 241001148683 Zostera marina Species 0.000 claims description 5
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N methylene hexane Natural products CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 claims description 5
- WPHGSKGZRAQSGP-UHFFFAOYSA-N methylenecyclohexane Natural products C1CCCC2CC21 WPHGSKGZRAQSGP-UHFFFAOYSA-N 0.000 claims description 5
- 239000003208 petroleum Substances 0.000 claims description 5
- 241000369835 Chondracanthus tenellus Species 0.000 claims description 4
- 241000668439 Gracilaria incurvata Species 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 21
- 108090000623 proteins and genes Proteins 0.000 abstract description 20
- 102000004169 proteins and genes Human genes 0.000 abstract description 19
- 102000008934 Muscle Proteins Human genes 0.000 abstract description 15
- 108010074084 Muscle Proteins Proteins 0.000 abstract description 15
- 102100025014 E3 ubiquitin-protein ligase TRIM63 Human genes 0.000 abstract description 14
- 101710164910 E3 ubiquitin-protein ligase TRIM63 Proteins 0.000 abstract description 14
- 102100040669 F-box only protein 32 Human genes 0.000 abstract description 14
- 101710191029 F-box only protein 32 Proteins 0.000 abstract description 14
- 108020004999 messenger RNA Proteins 0.000 abstract description 12
- 230000001965 increasing effect Effects 0.000 abstract description 10
- 230000017854 proteolysis Effects 0.000 abstract description 9
- 230000014616 translation Effects 0.000 abstract description 9
- 238000001243 protein synthesis Methods 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 229930014626 natural product Natural products 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 239000000469 ethanolic extract Substances 0.000 description 94
- 238000002360 preparation method Methods 0.000 description 43
- 210000003205 muscle Anatomy 0.000 description 29
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 25
- 210000000663 muscle cell Anatomy 0.000 description 20
- 238000004519 manufacturing process Methods 0.000 description 19
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 17
- 150000003839 salts Chemical class 0.000 description 16
- 238000007796 conventional method Methods 0.000 description 13
- 238000002156 mixing Methods 0.000 description 13
- 239000003755 preservative agent Substances 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 239000006071 cream Substances 0.000 description 11
- 239000004615 ingredient Substances 0.000 description 11
- 239000000796 flavoring agent Substances 0.000 description 10
- 241000545744 Hirudinea Species 0.000 description 9
- 244000299790 Rheum rhabarbarum Species 0.000 description 9
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 9
- 235000019634 flavors Nutrition 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 239000003086 colorant Substances 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- 239000006210 lotion Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- 241000237509 Patinopecten sp. Species 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 230000007850 degeneration Effects 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 235000013402 health food Nutrition 0.000 description 6
- -1 hemimalonate Chemical class 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 241000206572 Rhodophyta Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 229920002472 Starch Chemical class 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 229920002678 cellulose Chemical class 0.000 description 5
- 239000001913 cellulose Chemical class 0.000 description 5
- 235000010980 cellulose Nutrition 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000003205 fragrance Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 238000007911 parenteral administration Methods 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000004575 stone Substances 0.000 description 5
- 239000002562 thickening agent Substances 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 241000195628 Chlorophyta Species 0.000 description 4
- 241000254173 Coleoptera Species 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000000020 Nitrocellulose Substances 0.000 description 4
- 240000007594 Oryza sativa Species 0.000 description 4
- 235000007164 Oryza sativa Nutrition 0.000 description 4
- 229920001214 Polysorbate 60 Polymers 0.000 description 4
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 4
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 235000010419 agar Nutrition 0.000 description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 4
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 4
- 229940113124 polysorbate 60 Drugs 0.000 description 4
- 210000002027 skeletal muscle Anatomy 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Chemical class 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical class O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 235000007189 Oryza longistaminata Nutrition 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 241000199919 Phaeophyceae Species 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 101150057615 Syn gene Proteins 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 239000000783 alginic acid Substances 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 229960001126 alginic acid Drugs 0.000 description 3
- 150000004781 alginic acids Chemical class 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000007667 floating Methods 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 235000015203 fruit juice Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000003098 myoblast Anatomy 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 235000020637 scallop Nutrition 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 244000251953 Agaricus brunnescens Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 241001481710 Cerambycidae Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 241000498255 Enterobius vermicularis Species 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000218922 Magnoliophyta Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- 229920002230 Pectic acid Polymers 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 235000015895 biscuits Nutrition 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940112822 chewing gum Drugs 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- 229960004926 chlorobutanol Drugs 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- VWTINHYPRWEBQY-UHFFFAOYSA-N denatonium Chemical compound [O-]C(=O)C1=CC=CC=C1.C=1C=CC=CC=1C[N+](CC)(CC)CC(=O)NC1=C(C)C=CC=C1C VWTINHYPRWEBQY-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 206010014881 enterobiasis Diseases 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000010318 polygalacturonic acid Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000004804 winding Methods 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- NQRKYASMKDDGHT-UHFFFAOYSA-N (aminooxy)acetic acid Chemical compound NOCC(O)=O NQRKYASMKDDGHT-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 230000007730 Akt signaling Effects 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical class OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000001613 Gambling Diseases 0.000 description 1
- 241000173371 Garcinia indica Species 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 241000206581 Gracilaria Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical class CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical class NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000361919 Metaphire sieboldi Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- SOWBFZRMHSNYGE-UHFFFAOYSA-N Monoamide-Oxalic acid Natural products NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 241000269980 Pleuronectidae Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 108010034782 Ribosomal Protein S6 Kinases Proteins 0.000 description 1
- 102000009738 Ribosomal Protein S6 Kinases Human genes 0.000 description 1
- 241001653634 Russula vesca Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 240000001717 Vaccinium macrocarpon Species 0.000 description 1
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 1
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000013574 canned fruits Nutrition 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 235000004634 cranberry Nutrition 0.000 description 1
- 150000001944 cysteine derivatives Chemical class 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- UMNKXPULIDJLSU-UHFFFAOYSA-N dichlorofluoromethane Chemical compound FC(Cl)Cl UMNKXPULIDJLSU-UHFFFAOYSA-N 0.000 description 1
- 229940099364 dichlorofluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 101150046266 foxo gene Proteins 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000008202 granule composition Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000002035 hexane extract Substances 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 235000015094 jam Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000001360 methionine group Chemical class N[C@@H](CCSC)C(=O)* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 235000019691 monocalcium phosphate Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012875 nonionic emulsifier Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical class CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- CEAYCPAHSNTNGO-UHFFFAOYSA-M sodium;ethane-1,2-diamine;acetate Chemical compound [Na+].CC([O-])=O.NCCN CEAYCPAHSNTNGO-UHFFFAOYSA-M 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- JDVPQXZIJDEHAN-UHFFFAOYSA-N succinamic acid Chemical compound NC(=O)CCC(O)=O JDVPQXZIJDEHAN-UHFFFAOYSA-N 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q90/00—Cosmetics or similar toiletry preparations for specific uses not provided for in other groups of this subclass
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/202—Algae extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/46—Ultra high pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 해조류 추출물을 함유하는 근육 질환 예방 또는 치료용 또는 근 기능 개선용 조성물에 관한 것이다.The present invention relates to a composition for preventing or treating muscle diseases or improving muscle function, containing seaweed extract.
근위축(Muscle atrophy)이란 근육량의 점진적 감소에 의하여 발생하는 것으로, 근육의 약화 및 퇴행을 일컫는다(Cell, 119(7): 907-910, 2004). 근위축은 비활동, 산화적 스트레스, 만성 염증에 의해 촉진되며 근육 기능과 운동 능력을 약화시킨다(Clinical Nutrition, 26(5): 524-534, 2007). 근육기능을 결정짓는 가장 중요한 요소는 근육량이며, 이는 단백질 합성과 분해의 균형에 의해 유지된다. 근 위축증은 단백질 분해가 합성보다 더 일어날 때 발생한다(The International Journal of Biochemistry and Cell Biology, 37(10): 1985-1996, 2005).Muscle atrophy is caused by a gradual decrease in muscle mass, and refers to muscle weakness and degeneration (Cell, 119(7): 907-910, 2004). Muscular atrophy is promoted by inactivity, oxidative stress, and chronic inflammation and impairs muscle function and motor capacity (Clinical Nutrition, 26(5): 524-534, 2007). The most important factor in determining muscle function is muscle mass, which is maintained by a balance between protein synthesis and degradation. Muscular dystrophy occurs when protein degradation occurs more than synthetically (The International Journal of Biochemistry and Cell Biology, 37(10): 1985-1996, 2005).
근육 크기는 근육 내에서 일어나는 동화작용(anabolism)이나 이화작용(catabolism)을 유도하는 세포 내 신호전달 과정(signalling pathways)에 의해 조절되며 근육 단백질의 분해보다 합성을 유도하는 신호전달 반응이 많이 일어날 경우 근육 단백질 합성이 증가 되는데, 이는 근육 단백질 증가에 따른 근육 크기 증가(hypertrophy, 근비대)나 근섬유 수 증가(hyperplasia)로 나타난다(The Korea Journal of Sports Science, 20(3): 1551-1561, 2011).Muscle size is regulated by intracellular signaling pathways that induce anabolic or catabolism occurring in the muscle, and when there are more signaling reactions that induce synthesis rather than degradation of muscle proteins. Muscle protein synthesis is increased, which is indicated by an increase in muscle size (hypertrophy) or an increase in the number of muscle fibers (hyperplasia) according to an increase in muscle protein (The Korea Journal of Sports Science, 20(3): 1551-1561, 2011).
근 단백질 합성에 관여하는 인자들은 근 세포 내에서 phosphatidylinositol-3 kinase (PI3K)/Akt pathway의 자극을 기점으로 다운스트림 단백질(downstream proteins)을 인산화시킴으로써 단백질 합성을 유도한다. PI3K/Akt 신호전달에 의한 mammalian target of rapamycin (mTOR)의 활성은 세포 내에서 다양한 성장 신호를 통합하는 중심 성장 신호전달 인자로 인정되고 있다. mTOR는 mRNA translation을 개시하는 두 인자, 4E-binding protein (4EBP1)과 phosphorylated 70-kDa ribosomal S6 kinase (p70S6K)를 활성화시킴으로써 근 단백질 합성을 유도하여 근육량 증가에 기여한다(The Korea Journal of Sports Science, 20(3): 1551-1561, 2011; The International Journal of Biochemistry and Cell Biology, 43(9): 1267-1276, 2011). 반대로 전사 인자(transcription factor)인 forhead box (FoxO)가 세포질에서 핵 내로 이동하면 단백질 분해에 관여하는 E3 ubiquitin ligase인자 atrogin-1과 MuRF-1의 발현을 증가시킨다(Disease Models and Mechanisms, 6: 25-39, 2013). 이들의 발현량이 증가하면 근육 내의 단백질 분해가 촉진되어 근육량이 줄어들게 된다. 따라서 mTOR의 활성 촉진과 atrogin-1과 MuRF-1 발현 억제는 근육 단백질의 양을 증가시켜 근육량을 증가시키게 된다. Factors involved in muscle protein synthesis induce protein synthesis by phosphorylating downstream proteins from stimulation of the phosphatidylinositol-3 kinase (PI3K)/Akt pathway in muscle cells. The activity of the mammalian target of rapamycin (mTOR) by PI3K/Akt signaling is recognized as a central growth signaling factor that integrates various growth signals in cells. mTOR contributes to muscle mass increase by inducing muscle protein synthesis by activating two factors that initiate mRNA translation, 4E-binding protein (4EBP1) and phosphorylated 70-kDa ribosomal S6 kinase (p70S6K) (The Korea Journal of Sports Science, 20(3): 1551-1561, 2011; The International Journal of Biochemistry and Cell Biology, 43(9): 1267-1276, 2011). Conversely, when the forhead box (FoxO), a transcription factor, moves from the cytoplasm to the nucleus, it increases the expression of the E3 ubiquitin ligase factors atrogin-1 and MuRF-1, which are involved in protein degradation (Disease Models and Mechanisms, 6: 25). -39, 2013). When their expression level is increased, protein breakdown in muscle is promoted and muscle mass is reduced. Therefore, promoting mTOR activity and inhibiting the expression of atrogin-1 and MuRF-1 increase the amount of muscle protein, thereby increasing muscle mass.
일반적으로 해조류(海藻類, seaweeds)는 바다에 생육하고 육안으로 관찰할 수 있는 크기가 큰 다세포성 원생생물로 녹조류(green algae), 갈조류(brown algae), 그리고 홍조류(red algae)를 말한다. 녹조류는 청각(Codium fragile), 구멍갈파래(Ulva pertusa), 몽우리 청각(Codium contractum) 등을 포함하고, 갈조류는 고리매(Scytosiphon lomentaria), 곰피(Ecklonia stolonifera), 쇠미역(Costaria costata), 대황(Eisenia bicyclis), 넓미역(Undaria peterseniani), 넓패(Ishige sinicola), 괭생이모자반(Sargassum horneri), 톱니모자반(Sargassum serratifolium), 비틀대모자반(Sargassum sagamianum), 알쏭이모자반(Sargassum confusum), 꽈배기모자반(Sargassum siliquastrum), 지충이(Sargassum thunbergii) 등을 포함한다. 홍조류는 참풀가사리(Gloiopeltis tenax), 불등가사리(Gloiopeltis furcata), 참도박(Grateloupia elliptica), 잎꼬시래기(Gracilaria textorii), 돌가사리(Chondracanthus tenellus), 꼬시래기(Gracilaria verrucosa), 꼬불꼬시래기(Gracilaria incurvata), 갈고리가시우무(Hypnea japonica), 각시꼬시래기(Gracilaria bursa-pastoris), 볏붉은잎(Callophylis japonica) 등을 포함한다. 이 외에 거머리말(Zostera marina)이 현화식물로서 해양식물에 속한다. In general, seaweeds (seaweeds) are multicellular protozoa that grow in the sea and can be observed with the naked eye, and refer to green algae, brown algae, and red algae. Green algae include Codium fragile , Ulva pertusa , and Codium contractum , and brown algae include Scytosiphon lomentaria , Ecklonia stolonifera , Costaria costata , and rhubarb. Eisenia bicyclis ), Undaria peterseniani , Ishige sinicola , Sargassum horneri , Sargassum serratifolium , Sargassum sagamianum , Sargassum confusum , and ( Sargassum siliquastrum ), insectworm ( Sargassum thunbergii ), etc. Red algae include Gloiopeltis tenax , Gloiopeltis furcata , Grateloupia elliptica , Gracilaria textorii , Chondracanthus tenellus , Gracilaria verrucosa , and Gracilaria incurtacosa . These include Hypnea japonica , Gracilaria bursa-pastoris , and Callophylis japonica . Besides, Zostera marina is a flowering plant and belongs to marine plants.
그러나, 본 발명의 이전에는 해조류의 근육 질환 예방 및 치료 또는 근 기능 개선에 관해서는 알려진 바 없었다.However, prior to the present invention, it was not known about the prevention and treatment of muscle diseases or improvement of muscle function of seaweed.
이에 본 발명자들은 우수한 근 기능 조절 활성을 가지며 안전하게 적용될 수 있는 천연물질을 탐색한 결과, 괭생이모자반, 톱니모자반, 비틀대모자반, 알쏭이모자반, 꽈배기모자반, 지충이, 청각, 구멍갈파래, 몽우리 청각, 고리매, 곰피, 쇠미역, 대황, 넓미역, 넓패, 참풀가사리, 불등가사리, 참도박, 잎꼬시래기, 돌가사리, 꼬시래기, 꼬불꼬시래기, 갈고리가시우무, 각시꼬시래기, 볏붉은잎 또는 거머리말 등의 해조류 추출물이 근육 질환 예방 또는 치료, 또는 근 기능 개선 활성이 있음을 확인하고 본 발명을 완성하였다.Accordingly, the present inventors searched for a natural material that has excellent muscle function control activity and can be safely applied. As a result, it is possible to find a natural material that can be safely applied. , Gori mae, Gompi, Beef seaweed, Rhubarb, broad seaweed, broadleaf, champignon scallion, buldeung sashimi, champignon, leaf scallop, stone scallop, scallop scallop, scallop scallop, scallop scallop, scallop scallop, red crested leaves or leeches, etc. It was confirmed that the seaweed extract has the activity of preventing or treating muscle diseases, or improving muscle function, and the present invention was completed.
따라서, 본 발명의 목적은 해조류 추출물을 유효성분으로 함유하는 근육 질환 예방 또는 치료용, 또는 근 기능 개선용 조성물을 제공하는데 있다.Accordingly, an object of the present invention is to provide a composition for preventing or treating muscle diseases, or improving muscle function, containing an algae extract as an active ingredient.
상기 과제를 해결하기 위한 수단으로서, 본 발명은 As a means for solving the above problems, the present invention
해조류 추출물을 유효성분으로 함유하는 근육 질환 예방 또는 치료용 약학 조성물을 제공한다.It provides a pharmaceutical composition for preventing or treating muscle diseases containing seaweed extract as an active ingredient.
상기 과제를 해결하기 위한 또 다른 수단으로서, 본 발명은As another means for solving the above problem, the present invention
해조류 추출물을 유효성분으로 함유하는 근육 질환 예방 또는 근 기능 개선용 식품 조성물을 제공한다.It provides a food composition for preventing muscle disease or improving muscle function, containing seaweed extract as an active ingredient.
상기 과제를 해결하기 위한 또 다른 수단으로서, 본 발명은As another means for solving the above problem, the present invention
해조류 추출물을 유효성분으로 함유하는 근 기능 개선용 화장료 조성물을 제공한다.It provides a cosmetic composition for improving muscle function containing seaweed extract as an active ingredient.
본 발명의 바람직한 일실시예에 따르면, 상기 해조류 추출물은 괭생이모자반(Sargassum horneri), 톱니모자반(Sargassum serratifolium), 비틀대모자반(Sargassum sagamianum), 알쏭이모자반(Sargassum confusum), 꽈배기모자반(Sargassum siliquastrum), 지충이(Sargassum thunbergii), 청각(Codium fragile), 구멍갈파래(Ulva pertusa), 몽우리 청각(Codium contractum), 고리매(Scytosiphon lomentaria), 곰피(Ecklonia stolonifera), 쇠미역(Costaria costata), 대황(Eisenia bicyclis), 넓미역(Undaria peterseniani), 넓패(Ishige sinicola), 참풀가사리(Gloiopeltis tenax), 불등가사리(Gloiopeltis furcata), 참도박(Grateloupia elliptica), 잎꼬시래기(Gracilaria textorii), 돌가사리(Chondracanthus tenellus), 꼬시래기(Gracilaria verrucosa), 꼬불꼬시래기(Gracilaria incurvata), 갈고리가시우무(Hypnea japonica), 각시꼬시래기(Gracilaria bursa-pastoris), 볏붉은잎(Callophylis japonica) 및 거머리말(Zostera marina)로 이루어진 군에서 선택되는 하나 이상의 추출물일 수 있다.According to a preferred embodiment of the present invention, the seaweed extract is hoesaeng imojaban ( Sargassum horneri ), sawtooth hathaban ( Sargassum serratifolium ), beetle sagamianum ( Sargassum sagamianum ), alzoic hathaban ( Sargassum confusum ), pretzel raised hatban ( Sargassum siliquastrum) ), Earthworm ( Sargassum thunbergii ), Hearing ( Codium fragile ), Ulva pertusa , Codium contractum , Scytosiphon lomentaria , Ecklonia stolonifera , Ecklonia stolonifera , Costaria costata , rhubarb ( Eisenia bicyclis ), Undaria peterseniani , Ishige sinicola , Gloiopeltis tenax , Gloiopeltis furcata , Grateloupia elliptica , Gracilaria textorii Chondracanth, tenellus ), Gracilaria verrucosa , Gracilaria incurvata , Hypnea japonica , Gracilaria bursa-pastoris , red crested leaves ( Callophylis japonica ) and leeches (from Zostera marina ). It may be one or more extracts of choice.
본 발명의 바람직한 다른 일실시예에 따르면, 상기 해조류 추출물은 물, 탄소수 1 내지 6의 유기용매, 아임계 유체 및 초임계 유체로 이루어진 군에서 선택되는 하나 이상의 용매로 해조류를 추출하여 수득할 수 있다.According to another preferred embodiment of the present invention, the seaweed extract can be obtained by extracting seaweed with one or more solvents selected from the group consisting of water, an organic solvent having 1 to 6 carbon atoms, a subcritical fluid, and a supercritical fluid. .
본 발명의 바람직한 또 다른 일실시예에 따르면, 상기 탄소수 1 내지 6의 유기용매는 탄소수 1 내지 6의 알코올(alcohol), 아세톤(acetone), 에테르(ether), 벤젠(benzene), 클로로포름(chloroform), 에틸아세테이트(ethyl acetate), 메틸렌 클로라이드(methylene chloride), 헥산(hexane), 시클로헥산(cyclohexane) 및 석유에테르(petroleum ether)로 이루어진 군에서 선택되는 하나 이상의 용매일 수 있다.According to another preferred embodiment of the present invention, the organic solvent having 1 to 6 carbon atoms is an alcohol having 1 to 6 carbon atoms, acetone, ether, benzene, and chloroform. , Ethyl acetate, methylene chloride, hexane, cyclohexane, and petroleum ether may be one or more solvents selected from the group consisting of.
본 발명의 바람직한 다른 일실시예에 따르면, 상기 해조류 추출물은 100 MPa 이상의 초고압 조건 하에서 해조류를 추출하여 수득한 것일 수 있다.According to another preferred embodiment of the present invention, the seaweed extract may be obtained by extracting seaweed under ultra-high pressure conditions of 100 MPa or more.
본 발명의 바람직한 또 다른 일실시예에 따르면, 상기 근육 질환은 긴장감퇴증(atony), 근위축증(muscular atrophy), 근이영양증(muscular dystrophy), 근육 퇴화, 근무력증, 악액질(cachexia) 및 근육감소증(sarcopenia)으로 이루어진 군에서 선택되는 하나 이상의 질환일 수 있다.According to another preferred embodiment of the present invention, the muscle disease is atony, muscular atrophy, muscular dystrophy, muscle degeneration, myasthenia, cachexia, and sarcopenia. It may be one or more diseases selected from the group consisting of.
본 발명에 따른 해조류 추출물은 근 단백질 합성에 관여하는 p-mTOR의 단백질 발현 증가, 근 단백질 분해에 관여하는 MuRF-1과 atrogin-1의 mRNA 발현을 억제시킴에 따라, 근육량을 증대시키는데 우수한 효과가 있다. 또한, 본 발명은 천연물이므로 부작용 없이 인체에 안전하게 사용될 수 있어, 의약품, 식품 또는 화장품으로 유용하게 사용될 수 있다.The seaweed extract according to the present invention has an excellent effect in increasing muscle mass as it increases the protein expression of p-mTOR, which is involved in muscle protein synthesis, and suppresses the mRNA expression of MuRF-1 and atrogin-1, which are involved in muscle protein degradation. have. In addition, since the present invention is a natural product, it can be safely used for the human body without side effects, and thus can be usefully used as a medicine, food or cosmetics.
도 1은 C2C12 근육세포에서, 괭생이모자반, 톱니모자반 또는 비틀대모자반 에탄올 추출물 처리에 따른 p-mTOR의 단백질 발현을 측정한 결과를 보여준다.
도 2는 C2C12 근육세포에서, 알쏭이모자반, 꽈배기모자반 또는 지충이 에탄올 추출물 처리에 따른 p-mTOR의 단백질 발현을 측정한 결과를 보여준다.
도 3은 C2C12 근육세포에서, 괭생이모자반, 톱니모자반 또는 비틀대모자반 에탄올 추출물 처리에 따른 atrogin-1과 MuRF-1의 mRNA 발현을 측정한 결과를 보여준다.
도 4는 C2C12 근육세포에서, 알쏭이모자반, 꽈배기모자반 또는 지충이 에탄올 추출물 처리에 따른 atrogin-1과 MuRF-1의 mRNA 발현을 측정한 결과를 보여준다.1 shows the results of measuring the protein expression of p-mTOR in C2C12 muscle cells, according to the ethanol extract treatment of hoesaengyi, sawtooth, or beetles.
FIG. 2 shows the results of measuring the protein expression of p-mTOR in C2C12 muscle cells, according to the ethanol extract treatment of crypts, pretzel, or worms.
Figure 3 shows the results of measuring the mRNA expression of atrogin-1 and MuRF-1 in C2C12 muscle cells according to the ethanol extract treatment of hoesaengyi, sawtooth, or beetle.
Figure 4 shows the results of measuring the mRNA expression of atrogin-1 and MuRF-1 in C2C12 muscle cells, according to the ethanol extract treatment of alsonite, pretzel, or pinworm.
이하, 본 발명의 구성을 구체적으로 설명한다.Hereinafter, the configuration of the present invention will be described in detail.
본 발명은 해조류 추출물의 근육 질환 예방 또는 치료, 또는 근 기능 개선 용도; 해조류 추출물을 함유하는 근육 질환 예방 또는 치료용, 또는 근 기능 개선용 조성물; 또는 인간을 포함한 포유동물에 적용하는 해조류 추출물을 함유하는 근육 질환 예방 또는 치료, 또는 근 기능 개선 방법을 제공한다:The present invention is the use of seaweed extract for preventing or treating muscle diseases, or improving muscle function; A composition for preventing or treating muscle disease, or improving muscle function, containing seaweed extract; Or it provides a method for preventing or treating muscle disease, or improving muscle function, containing seaweed extract applied to mammals including humans:
본 명세서에서 ‘해조류’는 괭생이모자반, 톱니모자반, 비틀대모자반, 알쏭이모자반, 꽈배기모자반, 지충이, 청각, 구멍갈파래, 몽우리 청각, 고리매, 곰피, 쇠미역, 대황, 넓미역, 넓패, 참풀가사리, 불등가사리, 참도박, 잎꼬시래기, 돌가사리, 꼬시래기, 꼬불꼬시래기, 갈고리가시우무, 각시꼬시래기, 볏붉은잎 또는 거머리말 등을 포함하는 녹조류(green algae), 갈조류(brown algae), 홍조류(red algae) 또는 해양 현화식물이다. 상기 거머리말은 잘피라고도 불린다.In the present specification,'seaweed' refers to a hoesaeng hat band, a sawtooth hat band, a beetle hat band, a hatchet hat band, a hatchet hat band, a wormworm, aural, a hole snail, a monguri hearing, a gori mae, a gompi, a seaweed, rhubarb, a seaweed. , Green algae, brown algae, red algae, such as, green algae, scallop, red algae (red algae) or marine flowering plant. The leech horse is also called jaalpi.
본 명세서에서 ‘해조류 추출물’은 해조류를 추출하여 수득한 추출물을 의미한다. 해조류 추출물의 제조방법은 전술한 해조류 종류에 속하는 식물로부터 물, 탄소수 1 내지 6의 유기용매 및 아임계 또는 초임계 유체로 이루어진 군에서 선택된 하나 이상의 용매로 추출하는 것일 수 있으나, 특별히 이로 제한되는 것은 아니며, 통상의 추출 방법을 이용하여 전술한 해조류 종류에 속하는 식물로부터 유효성분을 추출할 수 있는 방법이라면 제한없이 포함할 수 있다. In the present specification, “seaweed extract” refers to an extract obtained by extracting seaweed. The method of preparing the seaweed extract may be extraction with one or more solvents selected from the group consisting of water, an organic solvent having 1 to 6 carbon atoms, and a subcritical or supercritical fluid from a plant belonging to the type of seaweed described above, but is particularly limited thereto. It may be included without limitation, as long as it is a method capable of extracting an active ingredient from a plant belonging to the above-described algae type using a conventional extraction method.
본 명세서에서, ‘근’은 심줄, 근육, 건을 포괄적으로 지칭하고,‘근 기능’은 근육의 수축에 의해 힘을 발휘하는 능력을 의미하며, 근육이 저항을 이겨내기 위하여 최대한으로 수축력을 발휘할 수 있는 능력인 근력, 근육이 주어진 중량에 얼마나 오랫동안 또는 얼마나 여러 번 수축과 이완을 반복할 수 있는지를 나타내는 능력인 근지구력, 단시간 내에 강한 힘을 발휘하는 능력인 순발력을 포함한다. 이러한 근 기능은 근육량에 비례한다. 용어‘근 기능 개선’은 근 기능을 더 좋게 향상시키는 것을 말한다.In the present specification,'muscle' refers to tendons, muscles, and tendons generically, and'muscle function' refers to the ability to exert power by contraction of the muscles, and the muscles can exert their contractile force as much as possible to overcome resistance. It includes muscle strength, which is the ability to be capable, muscle endurance, which is the ability to repeat contractions and relaxations for a given weight, for how long or many times, and quickness, which is the ability to exert strong power in a short time. These muscle functions are proportional to muscle mass. The term “improving muscle function” refers to improving muscle function for the better.
본 발명의 근육 질환 예방 또는 치료용, 또는 근 기능 개선용 조성물은 해조류 추출물을 단독으로 함유하거나 해조류 추출물과 그의 유사한 기능을 나타내는 유효성분을 추가로 1종 이상 함유할 수 있다. 추가적인 성분을 포함하게 되면 본 발명의 조성물의 근 기능 개선 효과가 더욱 증진될 수 있을 것이다. 상기 성분 추가 시에는 복합 사용에 따른 피부 안전성, 제형화의 용이성, 유효성분들의 안정성 등을 고려할 수 있다.The composition for preventing or treating muscle diseases of the present invention, or for improving muscle function, may contain seaweed extract alone or additionally contain one or more active ingredients exhibiting similar functions as seaweed extract. If additional components are included, the effect of improving muscle function of the composition of the present invention may be further enhanced. When the above ingredients are added, skin safety, ease of formulation, and stability of active ingredients can be taken into account in combination with use.
본 발명은 해조류 추출물을 유효성분으로 함유하는 근육 질환 예방 또는 치료용 약학 조성물, 근육 질환 예방 또는 근 기능 개선용 식품 조성물, 또는 근 기능 개선용 화장료 조성물을 제공한다.The present invention provides a pharmaceutical composition for preventing or treating muscle disease, a food composition for preventing or improving muscle disease, or a cosmetic composition for improving muscle function, containing the seaweed extract as an active ingredient.
한 구체예에서, 해조류 추출물은 특별히 이로 한정되는 것은 아니지만, 에탄올 추출물, 열수 추출물, 헥산 추출물, 에틸아세테이트 추출물, 초고압 추출물일 수 있다.In one embodiment, the seaweed extract is not particularly limited thereto, but may be an ethanol extract, a hot water extract, a hexane extract, an ethyl acetate extract, or an ultra-high pressure extract.
한 구체예에서, 해조류 추출물은 물, 탄소수 1 내지 6의 유기용매, 아임계 유체 및 초임계 유체로 이루어진 군으로부터 선택되는 하나 이상의 용매로 해조류를 추출하여 수득할 수 있다. 예를 들어, 해조류를 100 MPa 이상의 초고압 조건 하에서 추출하여 수득할 수도 있다. 필요한 경우에는 당업계에 공지된 방법에 따라 여과 및 농축 단계를 추가적으로 포함하여 제조할 수 있다.In one embodiment, the seaweed extract can be obtained by extracting the seaweed with one or more solvents selected from the group consisting of water, an organic solvent having 1 to 6 carbon atoms, a subcritical fluid, and a supercritical fluid. For example, seaweed can also be obtained by extraction under ultra-high pressure conditions of 100 MPa or more. If necessary, it can be prepared by additionally including filtration and concentration steps according to methods known in the art.
한 구체예에서, 상기 탄소수 1 내지 6의 유기용매는 탄소수 1 내지 6의 알코올(alcohol), 아세톤(acetone), 에테르(ether), 벤젠(benzene), 클로로포름(chloroform), 에틸아세테이트(ethyl acetate), 메틸렌 클로라이드(methylene chloride), 헥산(hexane), 시클로헥산(cyclohexane) 및 석유에테르(petroleum ether)로 이루어진 군 중에서 선택되는 하나 이상일 수 있다.In one embodiment, the organic solvent having 1 to 6 carbon atoms is an alcohol having 1 to 6 carbon atoms, acetone, ether, benzene, chloroform, ethyl acetate , Methylene chloride, hexane, cyclohexane, and petroleum ether may be at least one selected from the group consisting of.
또한, 본 발명의 해조류 추출물은 건조시킨 해조류를 식품가공에 적합한 정제수, 에탄올 및 아임계수 또는 초임계 이산화탄소를 이용하여 추출, 정제하여 얻을 수 있거나, 초고압 추출 장치를 이용하여 추출, 정제하여 얻을 수 있으며, 또는 해조류를 직접 압착하여 얻은 오일로부터 분리 정제하여 얻을 수 있다. 예를 들어, 100 MPa 이상의 초고압 조건 하에서 해조류를 추출하여 추출물을 수득할 수 있다.In addition, the seaweed extract of the present invention can be obtained by extracting and purifying dried seaweed using purified water suitable for food processing, ethanol and subcritical water or supercritical carbon dioxide, or extracted and purified using an ultra-high pressure extraction device. Alternatively, it can be obtained by separating and purifying the seaweed from oil obtained by directly pressing. For example, the extract can be obtained by extracting seaweed under ultra-high pressure conditions of 100 MPa or more.
상기 추출방법은 해조류에 적용하여 근기능 개선 조성물로 사용할 수 있다.The extraction method can be applied to seaweed and used as a composition for improving muscle function.
본 발명의 근육 질환 예방 또는 치료용 조성물이 약학 조성물인 경우, 근육 소모 또는 퇴화로 인한 근육 질환의 예방 또는 치료에 사용될 수 있다. 근육 소모 및 퇴화는 유전적 요인, 후천적 요인, 노화 등을 원인으로 발생하며, 근육 소모는 근육량의 점진적 손실, 근육, 특히 골격근 또는 수의근 및 심장근육의 약화 및 퇴행을 특징으로 한다. 이와 관련된 질환의 예로는 긴장감퇴증(atony), 근위축증(muscular atrophy), 근이영양증(muscular dystrophy), 근육 퇴화, 근무력증, 악액질(cachexia) 및 근육감소증(sarcopenia) 등을 들 수 있다. 본 발명의 조성물은 근육량 증대 효과가 있으며, 근육은 그 종류를 제한하지 않는다.When the composition for preventing or treating muscle diseases of the present invention is a pharmaceutical composition, it can be used for preventing or treating muscle diseases caused by muscle wasting or degeneration. Muscle wasting and degeneration occurs due to genetic factors, acquired factors, aging, etc., and muscle wasting is characterized by a gradual loss of muscle mass, weakness and degeneration of muscles, especially skeletal or voluntary muscles and heart muscles. Examples of related diseases include atony, muscular atrophy, muscular dystrophy, muscle degeneration, myasthenia, cachexia, and sarcopenia. The composition of the present invention has an effect of increasing muscle mass, and the type of muscle is not limited.
본 발명의 약학 조성물은 해조류 추출물을 약제학적으로 허용 가능한 염을 포함할 수 있다. 본 명세서에서 용어“약학적으로 허용 가능한”이란 생리학적으로 허용되고 인간에게 투여될 때, 통상적으로 알레르기 반응 또는 이와 유사한 반응을 일으키지 않는 것을 말하며, 상기 염으로는 약제학적으로 허용 가능한 유리산(free acid)에 의하여 형성된 산 부가염이 바람직하다. The pharmaceutical composition of the present invention may contain a pharmaceutically acceptable salt of the seaweed extract. In the present specification, the term "pharmaceutically acceptable" refers to a physiologically acceptable and when administered to a human, usually does not cause an allergic reaction or a similar reaction, and the salt is a pharmaceutically acceptable free acid (free Acid addition salts formed by acid) are preferred.
상기 해조류 추출물의 약제학적으로 허용 가능한 염은 유기산 또는 무기산을 이용하여 형성된 산 부가염일 수 있으며, 상기 유기산은 예를 들면 포름산, 아세트산, 프로피온산, 락트산, 부티르산, 이소부티르산, 트리플루오로아세트산, 말산, 말레산, 말론산, 푸마르산, 숙신산, 숙신산 모노아미드, 글루탐산, 타르타르산, 옥살산, 시트르산, 글리콜산, 글루쿠론산, 아스코르브산, 벤조산, 프탈산, 살리실산, 안트라닐산, 디클로로아세트산, 아미노옥시 아세트산, 벤젠술폰산, p-톨루엔술폰산 또는 메탄술폰산을 포함한다. 무기산은 예를 들면 염산, 브롬산, 황산, 인산, 질산, 탄산 또는 붕산을 포함한다. 산 부가염은 바람직하게는 염산염 또는 아세트산염 형태일 수 있으며, 보다 바람직하게는 염산염 형태일 수 있다.The pharmaceutically acceptable salt of the seaweed extract may be an acid addition salt formed using an organic or inorganic acid, and the organic acid is, for example, formic acid, acetic acid, propionic acid, lactic acid, butyric acid, isobutyric acid, trifluoroacetic acid, malic acid, Maleic acid, malonic acid, fumaric acid, succinic acid, succinic acid monoamide, glutamic acid, tartaric acid, oxalic acid, citric acid, glycolic acid, glucuronic acid, ascorbic acid, benzoic acid, phthalic acid, salicylic acid, anthranilic acid, dichloroacetic acid, aminooxyacetic acid, benzenesulfonic acid , p-toluenesulfonic acid or methanesulfonic acid. Inorganic acids include, for example, hydrochloric acid, bromic acid, sulfuric acid, phosphoric acid, nitric acid, carbonic acid or boric acid. The acid addition salt may be preferably in the form of hydrochloride or acetate, and more preferably in the form of hydrochloride.
상기 언급된 산 부가염은 a) 해조류 추출물 및 산을 직접 혼합하거나, b) 이들 중 한 가지를 용매 또는 함수 용매 중에 용해시키고 혼합시키거나, 또는 c) 해조류 추출물을 용매 또는 수하 용매 중의 산에 위치시키고 이들을 혼합하는 일반적인 염 제조방법으로 제조된다.The above-mentioned acid addition salts are either a) directly mixing seaweed extract and acid, b) dissolving and mixing one of them in a solvent or aqueous solvent, or c) placing seaweed extract in a solvent or acid in a submerged solvent. And it is prepared by a general salt preparation method of mixing them.
위와는 별도로 추가적으로 염이 가능한 형태는 가바염, 가바펜틴염, 프레가발린염, 니코틴산염, 아디페이트염, 헤미말론산염, 시스테인염, 아세틸시스테인염, 메티오닌염, 아르기닌염, 라이신염, 오르니틴염 또는 아스파르트산염 등이 있다. In addition to the above, additional salts are possible: gaba salt, gabapentin salt, pregabalin salt, nicotinate, adipate salt, hemimalonate, cysteine salt, acetylcysteine salt, methionine salt, arginine salt, lysine salt, ornithine salt or And aspartate.
또한, 본 발명의 근육 질환 예방 또는 치료용 약학 조성물은 약학적으로 허용 가능한 담체를 더 포함할 수 있다.In addition, the pharmaceutical composition for preventing or treating muscle diseases of the present invention may further include a pharmaceutically acceptable carrier.
약학적으로 허용 가능한 담체로는 예컨대, 경구 투여용 담체 또는 비경구 투여용 담체를 추가로 포함할 수 있다. 경구 투여용 담체는 락토스, 전분, 셀룰로스 유도체, 마그네슘 스테아레이트, 스테아르산 등을 포함할 수 있다. 또한 비경구 투여용 담체는 물, 적합한 오일, 식염수, 수성 글루코스 및 글리콜 등을 포함할 수 있다. 또한, 안정화제 및 보존제를 추가로 포함할 수 있다. 적합한 안정화제로는 아황산수소나트륨, 아황산나트륨 또는 아스코르브산과 같은 항산화제가 있다. 적합한 보존제로는 벤즈알코늄 클로라이드, 메틸- 또는 프로필-파라벤 및 클로로부탄올이 있다. 그 밖의 약학적으로 허용되는 담체로는 다음의 문헌에 기재되어 있는 것을 참고로 할 수 있다(Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Company, Easton, PA, 1995).The pharmaceutically acceptable carrier may further include, for example, a carrier for oral administration or a carrier for parenteral administration. Carriers for oral administration may include lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. In addition, the carrier for parenteral administration may include water, suitable oil, saline, aqueous glucose and glycol. In addition, it may further comprise a stabilizer and a preservative. Suitable stabilizers include antioxidants such as sodium hydrogen sulfite, sodium sulfite or ascorbic acid. Suitable preservatives are benzalkonium chloride, methyl- or propyl-paraben and chlorobutanol. Other pharmaceutically acceptable carriers may be referred to as those described in the following literature (Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Company, Easton, PA, 1995).
본 발명의 약학 조성물은 인간을 비롯한 포유동물에 어떠한 방법으로도 투여할 수 있다. 예를 들어, 경구 또는 비경구로 투여할 수 있으며, 비경구적인 투여방법으로는 이에 제한되는 것은 아니나, 정맥내, 근육내, 동맥내, 골수내, 경막내, 심장내, 경피, 피하, 복강내, 비강내, 장관, 국소, 설하 또는 직장내 투여일 수 있다.The pharmaceutical composition of the present invention can be administered to mammals including humans by any method. For example, it can be administered orally or parenterally, and parenteral administration methods are not limited thereto, but intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intracardiac, transdermal, subcutaneous, intraperitoneal , Intranasal, intestinal, topical, sublingual or rectal administration.
본 발명의 약학 조성물은 상술한 바와 같은 투여 경로에 따라 경구 투여용 또는 비경구 투여용 제제로 제형화 할 수 있다. 제형화할 경우에는 하나 이상의 완충제(예를 들어, 식염수 또는 PBS), 항산화제, 정균제, 킬레이트화제(예를 들어, EDTA 또는 글루타치온), 충진제, 증량제, 결합제, 아쥬반트(예를 들어, 알루미늄 하이드록사이드), 현탁제, 농후제 습윤제, 붕해제 또는 계면활성제, 희석제 또는 부형제를 사용하여 조제될 수 있다.The pharmaceutical composition of the present invention may be formulated as a formulation for oral administration or parenteral administration according to the route of administration as described above. When formulated, one or more buffers (e.g., saline or PBS), antioxidants, bacteriostatic agents, chelating agents (e.g., EDTA or glutathione), fillers, bulking agents, binders, adjuvants (e.g., aluminum hydroxide). Side), suspending agents, thickening agents, wetting agents, disintegrants or surfactants, diluents or excipients.
경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 액제, 겔제, 시럽제, 슬러리제, 현탁액 또는 캡슐제 등이 포함되며, 이러한 고형제제는 본 발명의 약학 조성물에 적어도 하나 이상의 부형제 예를 들면, 전분(옥수수 전분, 밀 전분, 쌀 전분, 감자 전분 등 포함), 칼슘카보네이트(calcium carbonate), 수크로스(sucrose), 락토오스(lactose), 덱스트로오스, 솔비톨, 만니톨, 자일리톨, 에리스리톨 말티톨, 셀룰로즈, 메틸 셀룰로즈, 나트륨 카르복시메틸셀룰로오즈 및 하이드록시프로필메틸-셀룰로즈 또는 젤라틴 등을 섞어 조제될 수 있다. 예컨대, 활성성분을 고체 부형제와 배합한 다음 이를 분쇄하고 적합한 보조제를 첨가한 후 과립 혼합물로 가공함으로써 정제 또는 당의정제를 수득할 수 있다.Solid preparations for oral administration include tablets, pills, powders, granules, liquids, gels, syrups, slurries, suspensions or capsules, and the like, and such solid preparations are at least one excipient in the pharmaceutical composition of the present invention, for example , Starch (including corn starch, wheat starch, rice starch, potato starch, etc.), calcium carbonate, sucrose, lactose, dextrose, sorbitol, mannitol, xylitol, erythritol maltitol, cellulose , Methyl cellulose, sodium carboxymethylcellulose, and hydroxypropylmethyl-cellulose or gelatin may be mixed and prepared. For example, tablets or dragees can be obtained by blending the active ingredient with a solid excipient, pulverizing it, adding a suitable auxiliary, and processing into a granule mixture.
단순한 부형제 이외에 마그네슘 스티레이트 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제 또는 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물 또는 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제 또는 보존제 등이 포함될 수 있다.In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral use include suspensions, liquid solutions, emulsions, or syrups, but may include various excipients, such as wetting agents, sweetening agents, fragrances, or preservatives, in addition to water or liquid paraffin, which are simple diluents commonly used. .
또한, 경우에 따라 가교결합 폴리비닐피롤리돈, 한천, 알긴산 또는 나트륨 알기네이트 등을 붕해제로 첨가할 수 있으며, 항응집제, 윤활제, 습윤제, 향료, 유화제 및 방부제 등을 추가로 포함할 수 있다.In addition, in some cases, cross-linked polyvinylpyrrolidone, agar, alginic acid, or sodium alginate may be added as a disintegrant, and an anti-coagulant, a lubricant, a wetting agent, a fragrance, an emulsifier and a preservative may be additionally included. .
비경구적으로 투여하는 경우 본 발명의 약학 조성물은 적합한 비경구용 담체와 함께 주사제, 경피 투여제 및 비강 흡입제의 형태로 당 업계에 공지된 방법에 따라 제형화될 수 있다. 상기 주사제의 경우에는 반드시 멸균되어야 하며 박테리아 및 진균과 같은 미생물의 오염으로부터 보호되어야 한다. 주사제의 경우 적합한 담체의 예로는 이에 한정되지는 않으나, 물, 에탄올, 폴리올(예를 들어, 글리세롤, 프로필렌 글리콜 및 액체 폴리에틸렌 글리콜 등), 이들의 혼합물 및/또는 식물유를 포함하는 용매 또는 분산매질일 수 있다. 보다 바람직하게는, 적합한 담체로는 행크스 용액, 링거 용액, 트리에탄올 아민이 함유된 PBS (phosphate buffered saline) 또는 주사용 멸균수, 10% 에탄올, 40% 프로필렌 글리콜 및 5% 덱스트로즈와 같은 등장 용액 등을 사용할 수 있다. 상기 주사제를 미생물 오염으로부터 보호하기 위해서는 파라벤, 클로로부탄올, 페놀, 소르빈산, 티메로살 등과 같은 다양한 항균제 및 항진균제를 추가로 포함할 수 있다. 또한, 상기 주사제는 대부분의 경우 당 또는 나트륨 클로라이드와 같은 등장화제를 추가로 포함할 수 있다.When administered parenterally, the pharmaceutical composition of the present invention may be formulated according to a method known in the art in the form of an injection, a transdermal administration, and a nasal inhalation agent together with a suitable parenteral carrier. In the case of such injections, they must be sterilized and protected from contamination by microorganisms such as bacteria and fungi. Examples of suitable carriers for injections include, but are not limited to, water, ethanol, polyol (eg, glycerol, propylene glycol and liquid polyethylene glycol, etc.), a mixture thereof and/or a solvent or dispersion medium containing vegetable oil. I can. More preferably, suitable carriers include Hanks' solution, Ringer's solution, phosphate buffered saline (PBS) containing triethanolamine or sterile water for injection, isotonic solutions such as 10% ethanol, 40% propylene glycol and 5% dextrose. Etc. can be used. In order to protect the injection from microbial contamination, various antibacterial and antifungal agents such as paraben, chlorobutanol, phenol, sorbic acid, thimerosal, and the like may be additionally included. In addition, the injection may further include an isotonic agent such as sugar or sodium chloride in most cases.
경피 투여제의 경우 연고제, 크림제, 로션제, 겔제, 외용액제, 파스타제, 리니멘트제, 에어롤제 등의 형태가 포함된다. 상기에서 ‘경피 투여’는 약학 조성물을 국소적으로 피부에 투여하여 약학 조성물에 함유된 유효한 양의 활성성분이 피부 내로 전달되는 것을 의미한다. In the case of transdermal administration, ointments, creams, lotions, gels, external solutions, pasta, liniment, and air rolls are included. In the above, "transdermal administration" means that the active ingredient in an effective amount contained in the pharmaceutical composition is delivered into the skin by topically administering the pharmaceutical composition to the skin.
흡입 투여제의 경우, 본 발명에 따라 사용되는 화합물은 적합한 추진제, 예를 들면, 디클로로플루오로메탄, 트리클로로플루오로메탄, 디클로로테트라플루오로에탄, 이산화탄소 또는 다른 적합한 기체를 사용하여, 가압 팩 또는 연무기로부터 에어로졸 스프레이 형태로 편리하게 전달 할 수 있다. 가압 에어로졸의 경우, 투약 단위는 계량된 양을 전달하는 밸브를 제공하여 결정할 수 있다. 예를 들면, 흡입기 또는 취입기에 사용되는 젤라틴 캡슐 및 카트리지는 화합물, 및 락토즈 또는 전분과 같은 적합한 분말 기제의 분말 혼합물을 함유하도록 제형화할 수 있다. 비경구 투여용 제형은 모든 제약 화학에 일반적으로 공지된 처방서인 문헌(Remington's Pharmaceutical Science, 15th Edition, 1975. Mack Publishing Company, Easton, Pennsylvania 18042, Chapter 87: Blaug, Seymour)에 기재되어 있다.In the case of inhalation dosages, the compounds used according to the invention can be prepared using a suitable propellant, for example dichlorofluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas, pressurized pack or It can be conveniently delivered from a nebulizer in the form of an aerosol spray. In the case of a pressurized aerosol, the dosage unit can be determined by providing a valve that delivers a metered amount. For example, gelatin capsules and cartridges for use in an inhaler or insufflator can be formulated to contain a powder mixture of the compound and a suitable powder base such as lactose or starch. Formulations for parenteral administration are described in Remington's Pharmaceutical Science, 15th Edition, 1975. Mack Publishing Company, Easton, Pennsylvania 18042, Chapter 87: Blaug, Seymour, a formula generally known for all pharmaceutical chemistry.
본 발명의 근육 질환 예방 또는 치료용 약학 조성물은 해조류 추출물을 유효량으로 포함할 때 바람직한 근육 질환 예방 또는 치료 효과를 제공할 수 있다. 본 명세서에서, '유효량'이라 함은 음성 대조군에 비해 그 이상의 반응을 나타내는 양을 말하며 바람직하게는 근 기능을 향상시키기에 충분한 양을 말한다. 본 발명의 약학 조성물에 해조류 추출물이 0.01 내지 99.99% 포함될 수 있으며, 잔량은 약학적으로 허용 가능한 담체가 차지할 수 있다. 본 발명의 약학 조성물에 포함되는 해조류 추출물의 유효량은 조성물이 제품화되는 형태 등에 따라 달라질 것이다.When the pharmaceutical composition for preventing or treating muscle diseases of the present invention contains an effective amount of seaweed extract, it may provide a desirable muscle disease prevention or treatment effect. In the present specification, the term'effective amount' refers to an amount that exhibits a higher response compared to the negative control group, and preferably refers to an amount sufficient to improve muscle function. The pharmaceutical composition of the present invention may contain 0.01 to 99.99% of seaweed extract, and the balance may be occupied by a pharmaceutically acceptable carrier. The effective amount of the seaweed extract contained in the pharmaceutical composition of the present invention will vary depending on the form in which the composition is commercialized.
본 발명의 약학 조성물의 총 유효량은 단일 투여량(single dose)으로 환자에게 투여될 수 있으며, 다중 투여량(multiple dose)으로 장기간 투여되는 분할 치료 방법(fractionated treatment protocol)에 의해 투여될 수 있다. 본 발명의 약학 조성물은 질환의 정도에 따라 유효성분의 함량을 달리할 수 있다. 비경구 투여시는 상기 해조류 추출물을 기준으로 하루에 체중 1 kg당 바람직하게 0.01 내지 50 mg, 더 바람직하게는 0.1 내지 30 mg의 양으로 투여되도록, 그리고 경구 투여시는 해조류 추출물을 기준으로 하루에 체중 1 kg당 바람직하게 0.01 내지 100 mg, 더 바람직하게는 0.01 내지 10 mg의 양으로 투여되도록 1 내지 수회에 나누어 투여할 수 있다. 그러나 상기 해조류 추출물의 용량은 약학 조성물의 투여 경로 및 치료 횟수뿐만 아니라 환자의 연령, 체중, 건강 상태, 성별, 질환의 중증도, 식이 및 배설율 등 다양한 요인들을 고려하여 환자에 대한 유효 투여량이 결정되는 것이므로, 이러한 점을 고려할 때 당 분야의 통상적인 지식을 가진 자라면 상기 해조류 추출물을 근육 질환 예방 및 치료를 위한 특정한 용도에 따른 적절한 유효 투여량을 결정할 수 있을 것이다. 본 발명에 따른 약학 조성물은 본 발명의 효과를 보이는 한 그 제형, 투여 경로 및 투여 방법에 특별히 제한되지 아니한다.The total effective amount of the pharmaceutical composition of the present invention may be administered to a patient in a single dose, and may be administered by a fractionated treatment protocol that is administered for a long time in multiple doses. The pharmaceutical composition of the present invention may vary the content of the active ingredient depending on the severity of the disease. When parenterally administered, the seaweed extract is preferably administered in an amount of 0.01 to 50 mg, more preferably 0.1 to 30 mg per 1 kg of body weight per day, and when administered orally, based on the seaweed extract per day. Per 1 kg of body weight, preferably 0.01 to 100 mg, more preferably 0.01 to 10 mg per 1 kg of body weight may be divided and administered in 1 to several times to be administered. However, the dose of the seaweed extract is determined by considering various factors such as the patient's age, weight, health status, sex, disease severity, diet and excretion rate, as well as the administration route and number of treatments of the pharmaceutical composition. Therefore, considering these points, those of ordinary skill in the art will be able to determine an appropriate effective dosage of the seaweed extract according to a specific use for preventing and treating muscle diseases. The pharmaceutical composition according to the present invention is not particularly limited in its formulation, route of administration, and method of administration as long as it exhibits the effects of the present invention.
본 발명의 근육 질환 예방 및 치료용 약학 조성물은 단독으로, 또는 수술, 방사선 치료, 호르몬 치료, 화학 치료 또는 생물학적 반응조절제를 사용하는 방법들과 병용하여 사용할 수 있다.The pharmaceutical composition for preventing and treating muscle diseases of the present invention may be used alone or in combination with surgery, radiation therapy, hormone therapy, chemotherapy, or methods using a biological response modifier.
본 발명의 근육 질환 예방 또는 치료용 약학 조성물은 또한 해조류 추출물을 유효성분으로 포함하는 외용제의 제형으로 제공할 수 있다.The pharmaceutical composition for preventing or treating muscle diseases of the present invention may also be provided in the form of an external preparation containing seaweed extract as an active ingredient.
본 발명의 근육 질환 예방 또는 치료용 약학 조성물을 피부외용제로 사용하는 경우, 추가로 지방 물질, 유기 용매, 용해제, 농축제 및 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 유화제, 비이온형 유화제, 충전제, 금속이온봉쇄제, 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 활성제, 친유성 활성제 또는 지질 소낭 등 피부 외용제에 통상적으로 사용되는 임의의 다른 성분과 같은 피부 과학 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다. 또한 상기 성분들은 피부 과학 분야에서 일반적으로 사용되는 양으로 도입될 수 있다.When the pharmaceutical composition for preventing or treating muscle diseases of the present invention is used as an external preparation for skin, additionally fatty substances, organic solvents, solubilizing agents, thickening and gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents ), fragrance, surfactant, water, ionic emulsifier, nonionic emulsifier, filler, sequestering agent, chelating agent, preservative, vitamin, blocker, wetting agent, essential oil, dye, pigment, hydrophilic activator, lipophilic activator Or it may contain adjuvants commonly used in the field of dermatology such as any other ingredients commonly used in skin external preparations such as lipid vesicles. In addition, the above ingredients may be introduced in amounts generally used in the field of dermatology.
본 발명의 근육 질환 예방 또는 치료용 약학 조성물이 피부 외용제로 제공될 경우, 이에 제한되는 것은 아니나, 연고, 패취, 겔, 크림 또는 분무제 등의 제형일 수 있다.When the pharmaceutical composition for preventing or treating muscle diseases of the present invention is provided as an external preparation for skin, it may be a formulation such as an ointment, patch, gel, cream, or spray, but is not limited thereto.
본 발명의 근육 질환 예방 또는 근 기능 개선용 조성물은 또한 식품 조성물일 수 있다. 본 발명의 근육 질환 예방 또는 근 기능 개선용이 식품 조성물인 경우, 근육 소모 또는 퇴화로 인한 근육 질환의 예방 또는 개선에 사용될 수 있다. 근육 소모 및 퇴화는 유전적 요인, 후천적 요인, 노화 등을 원인으로 발생하며, 근육 소모는 근육량의 점진적 손실, 근육, 특히 골격근 또는 수의근 및 심장근육의 약화 및 퇴행을 특징으로 한다. 이와 관련된 질환의 예로는 긴장감퇴증(atony), 근위축증(muscular atrophy), 근이영양증(muscular dystrophy), 근육 퇴화, 근무력증, 악액질(cachexia) 및 근육감소증(sarcopenia) 등을 들 수 있다. 본 발명의 조성물은 근육량 증대 효과가 있으며, 근육은 그 종류를 제한하지 않는다.The composition for preventing muscle disease or improving muscle function of the present invention may also be a food composition. In the case of a food composition for preventing muscle disease or improving muscle function of the present invention, it may be used for preventing or improving muscle disease caused by muscle wasting or degeneration. Muscle wasting and degeneration occurs due to genetic factors, acquired factors, aging, etc., and muscle wasting is characterized by a gradual loss of muscle mass, weakness and degeneration of muscles, especially skeletal or voluntary muscles and heart muscles. Examples of related diseases include atony, muscular atrophy, muscular dystrophy, muscle degeneration, myasthenia, cachexia, and sarcopenia. The composition of the present invention has an effect of increasing muscle mass, and the type of muscle is not limited.
본 발명의 식품 조성물은 기능성 식품(functional food), 영양 보조제(nutritional supplement), 건강식품(health food), 식품 첨가제(food additives) 및 사료 등의 모든 형태를 포함하며, 인간 또는 가축을 비롯한 동물을 취식대상으로 한다. 상기 유형의 식품 조성물은 당 업계에 공지된 통상적인 방법에 따라 다양한 형태로 제조할 수 있다.The food composition of the present invention includes all forms such as functional food, nutritional supplement, health food, food additives and feed, and contains humans or animals including livestock. It is targeted for eating. Food compositions of this type can be prepared in various forms according to conventional methods known in the art.
상기 유형의 식품 조성물은 당업계에 공지된 통상적인 방법에 따라 다양한 형태로 제조할 수 있다. 일반 식품으로는 이에 한정되지 않지만 음료(알콜성 음료 포함), 과실 및 그의 가공식품(예: 과일통조림, 병조림, 잼, 마아말레이드 등), 어류, 육류 및 그 가공식품(예: 햄, 소시지 콘비이프 등), 빵류 및 면류(예: 우동, 메밀국수, 라면, 스파게이트, 마카로니 등), 과즙, 각종 드링크, 쿠키, 엿, 유제품(예: 버터, 치이즈 등), 식용식물 유지, 마아가린, 식물성 단백질, 레토르트 식품, 냉동식품, 각종 조미료(예: 된장, 간장, 소스 등) 등에 상기 해조류 추출물을 첨가하여 제조할 수 있다. 또한, 영양보조제로는 이에 한정되지 않지만 캡슐, 타블렛, 환 등에 상기 해조류 추출물을 첨가하여 제조할 수 있다. 또한, 건강기능식품으로는 이에 한정되지 않지만 예를 들면, 상기 해조류 추출물 자체를 차, 쥬스 및 드링크의 형태로 제조하여 음용(건강음료)할 수 있도록 액상화, 과립화, 캡슐화 및 분말화하여 섭취할 수 있다. 또한, 상기 해조류 추출물을 식품 첨가제의 형태로 사용하기 위해서는 분말 또는 농축액 형태로 제조하여 사용할 수 있다. 또한, 상기 해조류 추출물과 근육 질환 예방 또는 근 기능 개선 효과가 있다고 알려진 공지의 활성 성분과 함께 혼합하여 조성물의 형태로 제조할 수 있다.Food compositions of this type can be prepared in various forms according to conventional methods known in the art. General foods include, but are not limited to, beverages (including alcoholic beverages), fruits and processed foods thereof (e.g., canned fruit, canned food, jam, marmalade, etc.), fish, meat and processed foods thereof (e.g. ham, sausage) Corn beef), bread and noodles (e.g. udon, buckwheat noodles, ramen, spagate, macaroni, etc.), fruit juice, various drinks, cookies, sweets, dairy products (e.g. butter, cheese, etc.), edible vegetable oil, margarine , Vegetable protein, retort food, frozen food, various seasonings (eg, miso, soy sauce, sauce, etc.), etc., can be prepared by adding the seaweed extract. In addition, nutritional supplements are not limited thereto, but may be prepared by adding the seaweed extract to capsules, tablets, pills, and the like. In addition, although not limited to this as a health functional food, for example, the seaweed extract itself can be prepared in the form of tea, juice, and drink and liquefied, granulated, encapsulated, and powdered so that it can be consumed (healthy beverage). I can. In addition, in order to use the seaweed extract in the form of a food additive, it may be prepared and used in the form of a powder or a concentrate. In addition, it may be prepared in the form of a composition by mixing the seaweed extract with known active ingredients known to have an effect of preventing muscle disease or improving muscle function.
본 발명의 근육 질환 예방 또는 근 기능 개선용 조성물이 건강음료 조성물로 이용되는 경우, 상기 건강음료 조성물은 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로 함유할 수 있다. 상술한 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드; 말토스, 슈크로스와 같은 디사카라이드; 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드; 자일리톨, 소르비톨, 에리트리톨 등의 당알콜일 수 있다. 감미제는 타우마틴, 스테비아 추출물과 같은 천연 감미제; 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 mL 당 일반적으로 약 0.01 ~ 0.04 g, 바람직하게는 약 0.02 ~ 0.03 g 이다.When the composition for preventing muscle disease or improving muscle function of the present invention is used as a health drink composition, the health drink composition may contain various flavors or natural carbohydrates as an additional component, such as a conventional beverage. The natural carbohydrates described above include monosaccharides such as glucose and fructose; Disaccharides such as maltose and sucrose; Polysaccharides such as dextrin and cyclodextrin; It may be a sugar alcohol such as xylitol, sorbitol, and erythritol. Sweeteners include natural sweeteners such as taumatin and stevia extract; Synthetic sweeteners such as saccharin and aspartame can be used. The ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 mL of the composition of the present invention.
본 발명의 해조류 추출물은 근육 질환 예방 또는 근 기능 개선용 식품 조성물의 유효성분으로 함유될 수 있는데, 그 양은 근육 질환 예방 또는 근 기능 개선용 작용을 달성하기에 유효한 양으로 특별히 한정되는 것은 아니나, 전체 조성물 총 중량에 대하여 0.01 내지 100 중량%인 것이 바람직하다. 본 발명의 식품 조성물은 해조류 추출물과 함께 근육 질환 예방 또는 근 기능 개선용 조성물에 효과가 있는 것으로 알려진 다른 활성 성분과 함께 혼합하여 제조될 수 있다.The seaweed extract of the present invention may be contained as an active ingredient of a food composition for preventing muscle disease or improving muscle function, and the amount is not particularly limited to an amount effective to achieve an action for preventing muscle disease or improving muscle function, but It is preferably 0.01 to 100% by weight based on the total weight of the composition. The food composition of the present invention may be prepared by mixing seaweed extract with other active ingredients known to be effective in preventing muscle disease or improving muscle function.
상기 외에 본 발명의 건강식품은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산, 펙트산의 염, 알긴산, 알긴산의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올 또는 탄산화제 등을 함유할 수 있다. 그 밖에 본 발명의 건강식품은 천연 과일주스, 과일주스 음료, 또는 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 혼합하여 사용할 수 있다. 이러한 첨가제의 비율은 크게 중요하진 않지만 본 발명의 조성물 100 중량부당 0.01 ~ 0.1 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the health food of the present invention includes various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid, salts of pectic acid, alginic acid, salts of alginic acid, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, It may contain glycerin, alcohol or a carbonating agent. In addition, the health food of the present invention may contain flesh for the manufacture of natural fruit juice, fruit juice beverage, or vegetable beverage. These ingredients may be used independently or in combination. The ratio of these additives is not very important, but it is generally selected from 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.
본 발명의 근 기능 개선용 조성물은 또한 화장료 조성물일 수 있다. 본 발명의 화장료 조성물은 해조류 추출물을 유효성분으로 함유하며 피부학적으로 허용 가능한 부형제와 함께 기초 화장품 조성물(화장수, 크림, 에센스, 클렌징 폼 및 클렌징 워터와 같은 세안제, 팩, 보디오일), 색조 화장품 조성물(화운데이션, 립스틱, 마스카라, 메이크업 베이스), 두발 제품 조성물(샴푸, 린스, 헤어컨디셔너, 헤어젤) 및 비누 등의 형태로 제조될 수 있다.The composition for improving muscle function of the present invention may also be a cosmetic composition. The cosmetic composition of the present invention contains seaweed extract as an active ingredient and, together with dermatologically acceptable excipients, basic cosmetic compositions (face wash such as lotion, cream, essence, cleansing foam and cleansing water, pack, body oil), color cosmetic composition (Foundation, lipstick, mascara, makeup base), hair product composition (shampoo, conditioner, hair conditioner, hair gel), and soap.
상기 부형제로는 이에 한정되지는 않으나 예를 들어, 피부연화제, 피부 침투 증강제, 착색제, 방향제, 유화제, 농화제 및 용매를 포함할 수 있다. 또한, 향료, 색소, 살균제, 산화방지제, 방부제 및 보습제 등을 추가로 포함할 수 있으며, 물성개선을 목적으로 점증제, 무기염류, 합성 고분자 물질 등을 포함할 수 있다. 예를 들면, 본 발명의 화장료 조성물로 세안제 및 비누를 제조하는 경우에는 통상의 세안제 및 비누 베이스에 상기 해조류 추출물을 첨가하여 용이하게 제조할 수 있다. 크림을 제조하는 경우에는 일반적인 수중유적형(O/W)의 크림베이스에 해조류 추출물 또는 이의 염을 첨가하여 제조할 수 있다. 여기에 향료, 킬레이트제, 색소, 산화방지제, 방부제 등과 물성개선을 목적으로 한 단백질, 미네랄, 비타민 등 합성 또는 천연소재를 추가로 첨가할 수 있다.The excipient is not limited thereto, but may include, for example, an emollient, a skin penetration enhancer, a colorant, a fragrance, an emulsifier, a thickener, and a solvent. In addition, flavoring, coloring, disinfecting agents, antioxidants, preservatives, moisturizing agents, etc. may be additionally included, and thickeners, inorganic salts, synthetic polymer materials, etc. may be included for the purpose of improving physical properties. For example, in the case of preparing a face wash and soap with the cosmetic composition of the present invention, it can be easily prepared by adding the seaweed extract to a common face wash and soap base. In the case of manufacturing a cream, it can be prepared by adding seaweed extract or salt thereof to a cream base of a general oil-in-water (O/W) type. Synthetic or natural materials such as proteins, minerals, vitamins, etc. for the purpose of improving physical properties, such as fragrances, chelating agents, coloring agents, antioxidants, preservatives, etc., may be additionally added.
본 발명의 화장료 조성물에 함유되는 해조류 추출물의 함량은 이에 한정되지 않지만 전체 조성물 총 중량에 대하여 0.001 내지 10 중량%인 것이 바람직하고, 0.01 내지 5중량%인 것이 더욱 바람직하다. 상기 함량이 0.001중량% 미만에서는 목적하는 항노화 또는 주름개선 효과를 기대할 수 없고, 10중량% 초과에서는 안전성 또는 제형상의 제조에 어려움이 있을 수 있다.The content of the seaweed extract contained in the cosmetic composition of the present invention is not limited thereto, but is preferably 0.001 to 10% by weight, more preferably 0.01 to 5% by weight, based on the total weight of the composition. When the content is less than 0.001% by weight, the desired anti-aging or wrinkle improvement effect cannot be expected, and when the content is more than 10% by weight, there may be difficulties in safety or formulation.
이하 본 발명을 실시예를 통하여 보다 상세하게 설명한다. Hereinafter, the present invention will be described in more detail through examples.
단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시 예에 한정되는 것은 아니다.However, the following examples are merely illustrative of the present invention, and the contents of the present invention are not limited to the following examples.
해조류 추출물의 제조Preparation of seaweed extract
<1-1> 괭생이모자반 에탄올 추출물의 제조<1-1> Preparation of Ethanol Extract of Sengyi Mojaban
건조된 괭생이모자반을 믹서로 분쇄한 다음, 분쇄한 괭생이모자반 시료 100 g을 100% 에탄올 1L에 넣고 24시간 상온에서 추출하였다. 추출된 시료는 와트만(Whatman) 2번 여과지로 감압여과하고, 여과된 추출액을 진공 회전 농축기로 농축하여 용매성분을 제거한 후 괭생이모자반 에탄올 추출물을 얻었다.After pulverizing the dried hoesaengi capricorne with a mixer, 100 g of the pulverized hoesengyi capricorne sample was added to 1L of 100% ethanol and extracted at room temperature for 24 hours. The extracted sample was filtered under reduced pressure with Whatman No. 2 filter paper, and the filtered extract was concentrated with a vacuum rotary concentrator to remove the solvent component, and then an ethanol extract of hoesaengyimojaban was obtained.
<1-2> 톱니모자반 에탄올 추출물의 제조<1-2> Preparation of ethanol extract of sawtooth hatch
건조된 시료 톱니모자반을 이용하여 실시예 1-1의 에탄올 추출물 제조 방법과 동일하게 톱니모자반 에탄올 추출물을 제조하였다.Using the dried sample sawtooth hatch, an ethanol extract of sawtooth hatch was prepared in the same manner as in the method for preparing the ethanol extract of Example 1-1.
<1-3> 비틀대모자반 에탄올 추출물의 제조<1-3> Preparation of Ethanol Extract of Torsillaris Capridae
건조된 시료 비틀대모자반을 이용하여 실시예 1-1의 에탄올 추출물 제조 방법과 동일하게 비틀대모자반 에탄올 추출물을 제조하였다.Using the dried sample tortoiseshell hatch, ethanol extract was prepared in the same manner as in the method for preparing the ethanol extract of Example 1-1.
<1-4> 알쏭이모자반 에탄올 추출물의 제조<1-4> Preparation of ethanol extract of Alsonimosaban
건조된 시료 알쏭이모자반을 이용하여 실시예 1-1의 에탄올 추출물 제조 방법과 동일하게 알쏭이모자반 에탄올 추출물을 제조하였다.The ethanol extract was prepared by using the dried sample alsonimozaban in the same manner as in the method for preparing the ethanol extract of Example 1-1.
<1-5> 꽈배기모자반 에탄올 추출물의 제조<1-5> Preparation of Ethanol Extract of Pretzel Capella
건조된 시료 꽈배기모자반을 이용하여 실시예 1-1의 에탄올 추출물 제조 방법과 동일하게 꽈배기모자반 에탄올 추출물을 제조하였다.Using the dried sample of the pretzel, the ethanol extract of the pretzel was prepared in the same manner as in the method for preparing the ethanol extract of Example 1-1.
<1-6> 지충이 에탄올 추출물의 제조<1-6> Preparation of ethanol extract of insect insects
건조된 시료 지충이를 이용하여 실시예 1-1의 에탄올 추출물 제조 방법과 동일하게 지충이 에탄올 추출물을 제조하였다.The ethanol extract was prepared in the same manner as in the method for preparing the ethanol extract of Example 1-1 by using the dried sample insecticide.
<1-7> 청각 에탄올 추출물의 제조<1-7> Preparation of auditory ethanol extract
건조된 시료 청각을 이용하여 실시예 1-1의 에탄올 추출물 제조 방법과 동일하게 청각 에탄올 추출물을 제조하였다.An auditory ethanol extract was prepared in the same manner as in the ethanol extract preparation method of Example 1-1 using the dried sample auditory.
<1-8> 구멍갈파래 에탄올 추출물의 제조<1-8> Preparation of Ethanol Extract
건조된 시료 구멍갈파래를 이용하여 실시예 1-1의 에탄올 추출물 제조 방법과 동일하게 구멍갈파래 에탄올 추출물을 제조하였다.Using the dried sample perilla, the ethanol extract was prepared in the same manner as in the method for preparing the ethanol extract of Example 1-1.
<1-9> 몽우리 청각 에탄올 추출물의 제조<1-9> Preparation of ethanol extract of Monguri auditory
건조된 시료 몽우리 청각을 이용하여 실시예 1-1의 에탄올 추출물 제조 방법과 동일하게 몽우리 청각 에탄올 추출물을 제조하였다.Using the dried sample Monguri hearing, an ethanol extract of Monguri hearing was prepared in the same manner as in the method for preparing the ethanol extract of Example 1-1.
<1-10> 고리매 에탄올 추출물의 제조<1-10> Preparation of ethanol extract of cyclic media
건조된 시료 고리매를 이용하여 실시예 1-1의 에탄올 추출물 제조 방법과 동일하게 고리매 에탄올 추출물을 제조하였다.Using the dried sample cyclic medium, a cyclic mae ethanol extract was prepared in the same manner as in the method for preparing the ethanol extract of Example 1-1.
<1-11> 곰피 에탄올 추출물의 제조<1-11> Preparation of ethanol extract of Gompi
건조된 시료 곰피를 이용하여 실시예 1-1의 에탄올 추출물 제조 방법과 동일하게 곰피 에탄올 추출물을 제조하였다.Using the dried sample gompi, an ethanol extract of gompi was prepared in the same manner as in the method for preparing the ethanol extract of Example 1-1.
<1-12> 쇠미역 에탄올 추출물의 제조<1-12> Preparation of Ethanol Extract of Beef Seaweed
건조된 시료 쇠미역을 이용하여 실시예 1-1의 에탄올 추출물 제조 방법과 동일하게 쇠미역 에탄올 추출물을 제조하였다.Using the dried seaweed sample, the ethanol extract of seaweed was prepared in the same manner as in the method for preparing the ethanol extract of Example 1-1.
<1-13> 대황 에탄올 추출물의 제조<1-13> Preparation of ethanol extract of rhubarb
건조된 시료 대황을 이용하여 실시예 1-1의 에탄올 추출물 제조 방법과 동일하게 대황 에탄올 추출물을 제조하였다.An ethanol extract of rhubarb was prepared in the same manner as in the method for preparing the ethanol extract of Example 1-1 using the dried sample rhubarb.
<1-14> 넓미역 에탄올 추출물의 제조<1-14> Preparation of Ethanol Extract of Broad Seaweed
건조된 시료 넓미역을 이용하여 실시예 1-1의 에탄올 추출물 제조 방법과 동일하게 넓미역 에탄올 추출물을 제조하였다.The ethanol extract of the seaweed extract was prepared in the same manner as in the method for preparing the ethanol extract of Example 1-1 using the dried sample seaweed.
<1-15> 넓패 에탄올 추출물의 제조<1-15> Preparation of Ethanol Extract
건조된 시료 넓패를 이용하여 실시예 1-1의 에탄올 추출물 제조 방법과 동일하게 넓패 에탄올 추출물을 제조하였다.An ethanol extract was prepared in the same manner as in the method for preparing the ethanol extract of Example 1-1 by using the dried specimen.
<1-16> 참풀가사리 에탄올 추출물의 제조<1-16> Preparation of Ethanol Extract of Astragalus
건조된 시료 참풀가사리를 이용하여 실시예 1-1의 에탄올 추출물 제조 방법과 동일하게 참풀가사리 에탄올 추출물을 제조하였다.Using the dried sample champignons, the ethanol extract of champignons was prepared in the same manner as in the method for preparing the ethanol extract of Example 1-1.
<1-17> 불등가사리 에탄올 추출물의 제조<1-17> Preparation of Ethanol Extract of Bulgari halibut
건조된 시료 불등가사리를 이용하여 실시예 1-1의 에탄올 추출물 제조 방법과 동일하게 불등가사리 에탄올 추출물을 제조하였다.Using the dried sample, the ethanol extract was prepared in the same manner as the ethanol extract preparation method of Example 1-1.
<1-18> 참도박 에탄올 추출물의 제조<1-18> Preparation of ethanol extract of Cham Gambling
건조된 시료 참도박을 이용하여 실시예 1-1의 에탄올 추출물 제조 방법과 동일하게 참도박 에탄올 추출물을 제조하였다.Using the dried sample champignons, champaign ethanol extract was prepared in the same manner as in the method for preparing the ethanol extract of Example 1-1.
<1-19> 잎꼬시래기 에탄올 추출물의 제조<1-19> Preparation of Ethanol Extract
건조된 시료 잎꼬시래기를 이용하여 실시예 1-1의 에탄올 추출물 제조 방법과 동일하게 잎꼬시래기 에탄올 추출물을 제조하였다.Ethanol extract was prepared in the same manner as in the method for preparing the ethanol extract of Example 1-1 by using the dried specimen.
<1-20> 돌가사리 에탄올 추출물의 제조<1-20> Preparation of ethanol extract of stone agar
건조된 시료 돌가사리를 이용하여 실시예 1-1의 에탄올 추출물 제조 방법과 동일하게 돌가사리 에탄올 추출물을 제조하였다.Using the dried sample stone agar, the ethanol extract of stone agar was prepared in the same manner as in the method for preparing the ethanol extract of Example 1-1.
<1-21> 꼬시래기 에탄올 추출물의 제조<1-21> Preparation of Ethanol Extract
건조된 시료 꼬시래기를 이용하여 실시예 1-1의 에탄올 추출물 제조 방법과 동일하게 꼬시래기 에탄올 추출물을 제조하였다.Using the dried sample, the ethanol extract was prepared in the same manner as the ethanol extract preparation method of Example 1-1.
<1-22> 꼬불꼬시래기 에탄올 추출물의 제조<1-22> Preparation of Ethanol Extract
건조된 시료 꼬불꼬시래기를 이용하여 실시예 1-1의 에탄올 추출물 제조 방법과 동일하게 꼬불꼬시래기 에탄올 추출물을 제조하였다.Using the dried sample, the ethanol extract was prepared in the same manner as in the method for preparing the ethanol extract of Example 1-1.
<1-23> 갈고리가시우무 에탄올 추출물의 제조<1-23> Preparation of Ethanol Extract of Glycoris Radix
건조된 시료 갈고리가시우무를 이용하여 실시예 1-1의 에탄올 추출물 제조 방법과 동일하게 갈고리가시우무 에탄올 추출물을 제조하였다.An ethanol extract was prepared by using the dried sample hook cranberry in the same manner as in the method for preparing the ethanol extract of Example 1-1.
<1-24> 각시꼬시래기 에탄올 추출물의 제조<1-24> Preparation of Ethanol Extract
시료 각시꼬시래기를 이용하여 실시예 1-1의 에탄올 추출물 제조 방법과 동일하게 각시꼬시래기 에탄올 추출물을 제조하였다.The ethanol extract was prepared in the same manner as in the method for preparing the ethanol extract of Example 1-1 using the sample Gakshikosiraegi.
<1-25> 볏붉은잎 에탄올 추출물의 제조<1-25> Preparation of ethanol extract of red rice leaves
건조된 시료 볏붉은잎을 이용하여 실시예 1-1의 에탄올 추출물 제조 방법과 동일하게 볏붉은잎 에탄올 추출물을 제조하였다.Using the dried sample red rice leaves, ethanol extract of red rice leaves was prepared in the same manner as in the method for preparing the ethanol extract of Example 1-1.
<1-26> 거머리말 에탄올 추출물의 제조<1-26> Preparation of ethanol extract of leech
건조된 시료 거머리말을 이용하여 실시예 1-1의 에탄올 추출물 제조 방법과 동일하게 거머리말 에탄올 추출물을 제조하였다.Using the dried sample leech, an ethanol extract of leech was prepared in the same manner as in the method for preparing the ethanol extract of Example 1-1.
C2C12 근육세포에서 모자반류 에탄올 추출물의 근육 생성 증가효과The Effect of Ethanol Extract on the Increase of Muscle Production in C2C12 Muscle Cells
근육세포인 C2C12 myoblast (ATCC, Manassas, VA, USA)를 10% fetal bovine serum (FBS; Hyclone, Logan, UT, USA)가 함유된 Dulbecco's modified Eagle's media (DMEM; Hyclone)와 함께 6-웰 플레이트에 1 X 105 cell/mL이 되도록 넣었다. 세포밀도가 약 80~85%가 되었을 때, 웰에 있는 배지를 제거하고 2% horse serum (HS; Hyclone)가 함유된 DMEM (Hyclone)에 실시예 1-1 내지 1-6의 모자반류 에탄올 추출물을 10 ㎍/mL의 농도로 세포에 처리하여 myotube 분화를 6일 동안 유도하였다. 배지는 2일에 한번씩 갈아주었다. 이때, 시료 대신 0.01% DMSO를 처리한 군을 대조군으로 하였다. 그 후 근육세포 분화 시 발현되는 주요 단백질 발현양을 알아보기 위해 Western blot을 수행하였다. Proteinase inhibitor cocktail (Sigma-Aldrich, St Louis, MO, USA)이 포함된 NP-40 완충용액(ELPIS-Biotech, Daejeon, Korea)으로 용해시켰다. 완충용액에 용해된 세포를 1.5 mL 튜브(tube)로 옮겨 13,000 rpm으로 10분간 원심분리하여 상등액만을 취하였다. 상등액을 브래드포드(Bradford, Bio-Rad Laboratories Inc., Hercules, CA, USA)법을 이용하여 정량하였다. 정량된 단백질을 5분간 끓인 후 SDS-PAGE로 전기영동하여 분리하였으며, 분리된 단백질을 니트로셀룰로스 막으로 전달하였다. p-mTOR 1차 항체(Cell signaling technology, Beverly, MA, USA)를 2.5% bovine serum albumin (BSA)에 1:1000의 비율로 희석하여 니트로셀룰로스 막에 전달된 단백질과 20시간 동안 상온에서 반응시켰다. 1차 항체를 반응시킨 다음 Tris-buffer Saline Tween 20 (TBST)을 이용하여 니트로셀룰로스 막을 10분간 3회 세척하였다. 세척 후, 1차 항체를 인지하는 horseradish peroxidase가 접합된 anti-rabbit 2차 항체(Bethyl Laboratories, Inc., Montgomery, TX, USA)를 2.5% BSA에 1:5000이 되도록 희석하여 니트로셀룰로스 막과 2시간 동안 상온에서 반응시켰으며, TBST를 이용하여 10분씩 3회에 걸쳐 세척하였다. Protein band는 ECL western blotting detection reagents (Amersham, Tokyo, Japan)를 사용하여 발색하였으며, G;BOX EF imaging system (Syngene, Cambridge, UK)을 이용하여 발색된 protein band를 확인하였다. 실시예 1-1 내지 1-3의 결과를 도 1에, 실시예 1-4 내지 1-6의 결과를 도 2에 나타내었다.Muscle cells, C2C12 myoblast (ATCC, Manassas, VA, USA) were added to a 6-well plate with Dulbecco's modified Eagle's media (DMEM; Hyclone) containing 10% fetal bovine serum (FBS; Hyclone, Logan, UT, USA). It was put so as to be 1 X 10 5 cells/mL. When the cell density reached about 80-85%, the medium in the well was removed and the ethanol extract of mother and child of Examples 1-1 to 1-6 in DMEM (Hyclone) containing 2% horse serum (HS; Hyclone) The cells were treated at a concentration of 10 μg/mL to induce myotube differentiation for 6 days. The medium was changed once every 2 days. At this time, the group treated with 0.01% DMSO instead of the sample was used as a control. After that, Western blot was performed to determine the expression level of major proteins expressed during differentiation of muscle cells. It was dissolved in NP-40 buffer solution (ELPIS-Biotech, Daejeon, Korea) containing proteinase inhibitor cocktail (Sigma-Aldrich, St Louis, MO, USA). Cells dissolved in the buffer solution were transferred to a 1.5 mL tube, centrifuged at 13,000 rpm for 10 minutes, and only the supernatant was taken. The supernatant was quantified using the Bradford (Bradford, Bio-Rad Laboratories Inc., Hercules, CA, USA) method. After boiling the quantified protein for 5 minutes, it was separated by electrophoresis by SDS-PAGE, and the separated protein was transferred to a nitrocellulose membrane. The p-mTOR primary antibody (Cell signaling technology, Beverly, MA, USA) was diluted in 2.5% bovine serum albumin (BSA) at a ratio of 1:1000 and reacted with the protein delivered to the nitrocellulose membrane for 20 hours at room temperature. . After reacting with the primary antibody, the nitrocellulose membrane was washed 3 times for 10 minutes using Tris-buffer Saline Tween 20 (TBST). After washing, an anti-rabbit secondary antibody conjugated with horseradish peroxidase that recognizes the primary antibody (Bethyl Laboratories, Inc., Montgomery, TX, USA) was diluted to 1:5000 in 2.5% BSA, followed by a nitrocellulose membrane and 2 It was reacted at room temperature for a period of time, and washed three times for 10 minutes each using TBST. Protein bands were colored using ECL western blotting detection reagents (Amersham, Tokyo, Japan), and the colored protein bands were confirmed using G;BOX EF imaging system (Syngene, Cambridge, UK). The results of Examples 1-1 to 1-3 are shown in FIG. 1 and the results of Examples 1-4 to 1-6 are shown in FIG. 2.
그 결과, 도 1에 나타낸 바와 같이 괭생이모자반, 톱니모자반 또는 비틀대모자반 에탄올 추출물을 처리함에 따라, 도 2에 나타낸 바와 같이 알쏭이모자반, 꽈배기모자반 또는 지충이 에탄올 추출물을 처리함에 따라 C2C12 근육세포에서 p-mTOR의 단백질 발현양이 증가한 것을 확인할 수 있다. 이는 본 발명의 해조류 에탄올 추출물이 근육세포 내에서 근육 생성을 증가시키는 능력이 우수하다는 것을 의미한다.As a result, C2C12 muscle cells as shown in FIG. It can be seen that the amount of protein expression of p-mTOR increased. This means that the algae ethanol extract of the present invention has excellent ability to increase muscle production in muscle cells.
L6 근육세포에서 해조류 에탄올 추출물의 근육 생성 증가효과Effect of Ethanol Extract from Seaweed on Increased Muscle Production in L6 Muscle Cells
근육세포인 L6 myoblast (ATCC)에 실시예 1-7 내지 1-26의 해조류 에탄올 추출물을 10 ㎍/mL의 농도로 처리하여 상기 실시예 2와 동일한 방법으로 실험을 진행하였다. ECL 웨스턴 블롯팅 검출 시약(western blotting detection reagents) (Amersham)으로 발색된 단백질 밴드를 Image J software (National Institutes of Health, NIH, Bethesda, MD, USA)를 이용하여 정량처리 하였다. 대조군의 단백질 발현양을 100% 라고 했을 때, 각 추출물에 대한 상대적인 단백질 발현양을 표 1에 나타내었다. In the muscle cells L6 myoblast (ATCC), the ethanol extracts of the seaweeds of Examples 1-7 to 1-26 were treated at a concentration of 10 μg/mL, and the experiment was conducted in the same manner as in Example 2. Protein bands developed with ECL western blotting detection reagents (Amersham) were quantified using Image J software (National Institutes of Health, NIH, Bethesda, MD, USA). When the protein expression level of the control group is 100%, the relative protein expression levels for each extract are shown in Table 1.
그 결과, 표 1에 나타낸 바와 같이 다양한 해조류 에탄올 추출물을 처리함에 따라 L6 근육세포에서 p-mTOR의 단백질 발현양이 증가한 것을 확인할 수 있다. 이는 본 발명의 다양한 해조류 추출물이 근육세포 내에서 근육 생성을 증가시키는 능력이 우수하다는 것을 의미한다.As a result, as shown in Table 1, it can be seen that the amount of protein expression of p-mTOR in L6 muscle cells increased as various algae ethanol extracts were treated. This means that the various seaweed extracts of the present invention have excellent ability to increase muscle production in muscle cells.
C2C12 근육세포에서 모자반류 에탄올 추출물의 근 단백질 분해 억제 활성Inhibitory Activity of Ethanol Extract from Maternal Ethanol in C2C12 Muscle Cells
근육세포인 C2C12(ATCC)를 10% FBS (Hyclone)가 함유된 DMEM (Hyclone)과 함께 6-웰 플레이트에 1 X 105 cell/mL이 되도록 넣었다. 세포밀도가 약 80~85%가 되었을 때, 웰에 있는 배지를 제거하고 2% HS (Hyclone)가 함유된 DMEM (Hyclone)을 세포에 처리하여 myotube 분화를 유도하였다. 2일에 한 번씩 새로운 배지로 교체하여 총 6일 동안 분화를 진행하였다. 분화 후, 50 ng/mL tumor necrosis factor alpha (TNF-α; PeproTech, Rocky Hills, NJ, USA)가 함유된 DMEM (Hyclone)에 상기 실시예 1-1 내지 1-6의 모자반류 에탄올 추출물을 10 ㎍/mL의 농도로 세포에 처리하였다. 12시간 후, TRIzol시약(Invitrogen, Carlsbad, CA, USA)을 사용하여 총 RNA를 분리하였다. 분리한 총 RNA는 나노드랍(NanoDrop 1000; Thermo Fisher Scientific Inc., MA, USA)을 이용하여 정량하였다. 정량된 16 μL의 RNA를 Reverse Transcriptase Premix (ELPIS-Biotech)와 PCR 기계(Gene Amp PCR System 2700; Applied Biosystems, MA, USA)를 이용하여 42℃ 55분, 70℃ 15분의 조건에서 cDNA로 합성하였다. 16 μL의 생성된 cDNA 중 3 μL의 cDNA, 하기의 특정 프라이머(Bioneer, Daejeon, Korea) 그리고 PCR premix (ELPIS-Biotech)로 95℃에서 30초, 60℃에서 1분, 72℃에서 1분을 30번 반복하여 PCR을 수행하였다. C2C12 (ATCC), a muscle cell, was placed in a 6-well plate with DMEM (Hyclone) containing 10% FBS (Hyclone) at 1
Atrogin-1Atrogin-1
Forward primer: 5'-CAGTGATCCATTCTGTTCATCCTTG-3' (서열번호 1)Forward primer: 5'-CAGTGATCCATTCTGTTCATCCTTG-3' (SEQ ID NO: 1)
Reverse primer: 5'-TTATTTCCAGCCAAATGGAGAGAGA-3' (서열번호 2)Reverse primer: 5'-TTATTTCCAGCCAAATGGAGAGAGA-3' (SEQ ID NO: 2)
MuRF-1MuRF-1
Forward primer: 5'-TCTGCACTTAGAACACATAGCAGAG-3' (서열번호 3)Forward primer: 5'-TCTGCACTTAGAACACATAGCAGAG-3' (SEQ ID NO: 3)
Reverse primer: 5'-TCTCCTTCTTCATTGGTGTTCTTCT-3' (서열번호 4)Reverse primer: 5'-TCTCCTTCTTCATTGGTGTTCTTCT-3' (SEQ ID NO: 4)
β-Actinβ-Actin
Forward primer: 5'-CAGCTCAGTAACAGTCCGCC-3' (서열번호 5)Forward primer: 5'-CAGCTCAGTAACAGTCCGCC-3' (SEQ ID NO: 5)
Reverse primer: 5'-TCACTATTGGCAACGAGCGG-3' (서열번호 6)Reverse primer: 5'-TCACTATTGGCAACGAGCGG-3' (SEQ ID NO: 6)
PCR 결과 증폭된 cDNA를 1.5% agarose gel로 전기영동하여 분리하였으며, G;BOX EF imaging system (Syngene)을 이용하여 cDNA 밴드를 확인하였다. 실시예 1-1 내지 1-3의 결과를 도 3에, 실시예 1-4 내지 1-6의 결과를 도 4에 나타내었다.As a result of PCR, the amplified cDNA was separated by electrophoresis with 1.5% agarose gel, and the cDNA band was confirmed using a G;BOX EF imaging system (Syngene). The results of Examples 1-1 to 1-3 are shown in FIG. 3, and the results of Examples 1-4 to 1-6 are shown in FIG.
그 결과, 도 3에 나타낸 바와 같이 괭생이모자반, 톱니모자반 또는 비틀대모자반 에탄올 추출물을 처리함에 따라, C2C12 근육세포에서 atrogin-1과 MuRF-1의 mRNA 발현량이 감소하였으며, 도 4에 나타낸 바와 같이 알쏭이모자반, 꽈배기모자반 또는 지충이 에탄올 추출물을 처리함에 따라, atrogin-1과 MuRF-1의 mRNA 발현량이 감소한 것을 확인할 수 있었다. 이는 본 발명의 해조류 에탄올 추출물이 근육세포 내에서 근 단백질 분해를 억제하는 능력이 우수하다는 것을 의미한다.As a result, as shown in FIG. 3, as shown in FIG. 3, the mRNA expression levels of atrogin-1 and MuRF-1 were decreased in C2C12 muscle cells, as shown in FIG. 4, as the ethanol extract was treated. It was confirmed that the mRNA expression levels of atrogin-1 and MuRF-1 were decreased as the ethanol extract was treated with the larvae, pretzel, or pinworm. This means that the ethanol extract of seaweed of the present invention has excellent ability to inhibit muscle protein degradation in muscle cells.
해조류의 근 단백질 분해 억제 활성Inhibitory activity of seaweed's muscle protein degradation
근육세포인 L6 myoblast (ATCC)에 실시예 1-7 내지 1-26의 해조류 에탄올 추출물을 10 ㎍/mL의 농도로 처리하여 하기의 특정 프라이머(Bioneer)로 상기 실시예 4와 동일한 방법으로 RT-PCR을 진행하였다.L6 myoblast (ATCC), which is muscle cells, was treated with the ethanol extract of seaweeds of Examples 1-7 to 1-26 at a concentration of 10 μg/mL, and RT- in the same manner as in Example 4 with a specific primer (Bioneer) below. PCR was carried out.
Atrogin-1Atrogin-1
Forward primer: 5'-CCCTGATGGCATCGCCCAA-3' (서열번호 7)Forward primer: 5'-CCCTGATGGCATCGCCCAA-3' (SEQ ID NO: 7)
Reverse primer: 5'-AGGTCCCGCCCATCGCTCA-3' (서열번호 8)Reverse primer: 5'-AGGTCCCGCCCATCGCTCA-3' (SEQ ID NO: 8)
MuRF-1MuRF-1
Forward primer: 5'-GAAATGCTATGGAGAACCTGGAGAA-3' (서열번호 9)Forward primer: 5'-GAAATGCTATGGAGAACCTGGAGAA-3' (SEQ ID NO: 9)
Reverse primer: 5'-ATTCCTGCTTGTAGATGTCGATGAT-3' (서열번호 10)Reverse primer: 5'-ATTCCTGCTTGTAGATGTCGATGAT-3' (SEQ ID NO: 10)
β-Actinβ-Actin
Forward primer: 5'-AGCCATGTACGTAGCCATCC-3' (서열번호 11)Forward primer: 5'-AGCCATGTACGTAGCCATCC-3' (SEQ ID NO: 11)
Reverse primer: 5'-CTCTCAGCTGTGGTGCTGAA-3' (서열번호 12)Reverse primer: 5'-CTCTCAGCTGTGGTGCTGAA-3' (SEQ ID NO: 12)
G;BOX EF imaging system (Syngene)을 이용하여 확인한 cDNA 밴드를 Image J software (NIH)를 통해 정량처리 하였다. TNF-α를 처리하여 atrophy를 유도한 군의 cDNA 발현양을 100%라고 했을 때, 각 추출물에 대한 상대적인 atrogin-1의 mRNA 발현량을 표 2, MuRF-1의 mRNA 발현량을 표 3에 나타내었다. The cDNA bands identified using G;BOX EF imaging system (Syngene) were quantified through Image J software (NIH). Assuming that the cDNA expression level of the group inducing atrophy by treatment with TNF-α is 100%, the relative mRNA expression level of atrogin-1 for each extract is shown in Table 2, and the mRNA expression level of MuRF-1 is shown in Table 3. Done.
그 결과, 본 발명의 해조류 추출물을 처리함에 따라 표 2에 나타낸 바와 같이 근육세포에서 atrogin-1의 mRNA 발현이 감소하고 표 3에 나타낸 바와 같이 MuRF-1의 mRNA 발현이 감소함을 알 수 있었다. 이는 본 발명의 해조류 추출물이 근육세포 내에서 근 단백질 분해를 억제하는 능력이 우수하다는 것을 의미한다.As a result, as shown in Table 2, as shown in Table 2, the mRNA expression of atrogin-1 decreased and the mRNA expression of MuRF-1 decreased as shown in Table 3. This means that the seaweed extract of the present invention has excellent ability to inhibit muscle protein degradation in muscle cells.
이하, 본 발명에 따른 상기 해조류 추출물을 유효성분으로 함유하는 의약품, 식품 또는 화장품의 제조예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다. 상기 근육 질환 예방 및 치료 또는 근 기능 개선 효과가 우수한 해조류 추출물을 가지고 하기와 같은 조성성분 및 조성비에 따라 제조예 1 내지 3의 의약품, 식품 또는 화장료 조성물을 통상적인 방법에 따라서 제조하였다.Hereinafter, examples of preparation of pharmaceuticals, foods, or cosmetics containing the seaweed extract according to the present invention as an active ingredient will be described, but the present invention is not intended to limit them, but is intended to be described in detail. The pharmaceutical, food, or cosmetic compositions of Preparation Examples 1 to 3 were prepared according to the following compositional components and composition ratios with the seaweed extract having excellent muscle disease prevention and treatment or muscle function improvement effect according to a conventional method.
[제조예 1] 의약품[Production Example 1] Pharmaceuticals
<1-1> 산제<1-1> powder
상기 실시예 <1-1> 내지 <1-26> 중 어느 하나 이상의 해조류 추출물 50 mg, 결정셀룰로오즈 2 g을 혼합한 후 통상의 산제 제조방법에 따라서 기밀포에 충진하여 산제를 제조하였다.After mixing 50 mg of seaweed extract and 2 g of crystalline cellulose from any one or more of Examples <1-1> to <1-26>, a powder was prepared by filling the airtight cloth according to a conventional powder preparation method.
<1-2> 정제<1-2> tablet
상기 실시예 <1-1> 내지 <1-26> 중 어느 하나 이상의 해조류 추출물 50 mg, 결정셀룰로오즈 400 mg, 스테아린산 마그네슘 5 mg을 혼합한 후 통상의 정제 제조방법에 따라서 타정하여 정제를 제조하였다.After mixing 50 mg of seaweed extract, 400 mg of crystalline cellulose, and 5 mg of magnesium stearate in any one of Examples <1-1> to <1-26>, tablets were prepared by tableting according to a conventional tablet preparation method.
<1-3> 캡슐제<1-3> Capsule
상기 실시예 <1-1> 내지 <1-26> 중 어느 하나 이상의 해조류 추출물 30 mg, 유청단백질 100 mg, 결정셀룰로오즈 400 mg, 스테아린산 마그네슘 6 mg을 혼합한 후 통상의 캡슐제 제조방법에 따라서 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.Gelatin according to a conventional capsule preparation method after mixing 30 mg of seaweed extract of any one or more of Examples <1-1> to <1-26>, 100 mg of whey protein, 400 mg of crystalline cellulose, and 6 mg of magnesium stearate. Capsules were prepared by filling in capsules.
[제조예 2] 식품[Production Example 2] Food
<2-1> 건강식품의 제조<2-1> Manufacture of health food
상기 실시예 <1-1> 내지 <1-26> 중 어느 하나 이상의 해조류 추출물 1000 mg, 비타민 A 아세테이트 70 ug, 비타민 E 1.0 mg, 비타민 B1 0.13 mg, 비타민 B2 0.15 mg, 비타민 B6 0.5 mg, 비타민 B12 0.2 ug, 비타민 C 10 mg, 비오틴 10 ug, 니코틴산아미드 1.7 mg, 엽산 50 ug, 판토텐산 칼슘 0.5 mg, 황산제1철 1.75 mg, 산화아연 0.82 mg, 탄산마그네슘 25.3 mg, 제1인산칼륨 15 mg, 제2인산칼슘 55 mg, 구연산칼륨 90 mg, 탄산칼슘 100 mg, 염화마그네슘 24.8 mg를 혼합하여 제조할 수 있으며, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강식품 조성물 제조에 사용할 수 있다.Examples <1-1> to <1-26> of any one or more seaweed extract 1000 mg, vitamin A acetate 70 ug, vitamin E 1.0 mg, vitamin B1 0.13 mg, vitamin B2 0.15 mg, vitamin B6 0.5 mg, vitamin B12 0.2 ug,
<2-2> 건강음료의 제조<2-2> Manufacture of health drinks
상기 실시예 <1-1> 내지 <1-26> 중 어느 하나 이상의 해조류 추출물 1000 mg, 구연산 1000 mg, 올리고당 100 g, 매실농축액 2 g, 타우린 1 g에 정제수를 가하여 전체 900 mL 통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간동안 85에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2 L용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 건강음료 조성물 제조에 사용할 수 있다.Any one or more of the above Examples <1-1> to <1-26> 1000 mg of seaweed extract, 1000 mg of citric acid, 100 g of oligosaccharide, 2 g of plum concentrate, and 1 g of taurine were added with purified water for a total of 900 mL of normal health drink After mixing the above ingredients according to the manufacturing method, after stirring and heating at 85 for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed and sterilized, and then stored in a refrigerator for use in preparing a health drink composition. I can.
<2-3> 츄잉껌<2-3> Chewing gum
껌 베이스 20 중량%, 설탕 76.9 중량%, 향료 1 중량% 및 물 2 중량% 와 상기 실시예 <1-1> 내지 <1-26> 중 어느 하나 이상의 해조류 추출물 0.1 중량%를 배합하여 통상의 방법으로 츄잉껌을 제조하였다.A conventional method by combining 20% by weight of gum base, 76.9% by weight of sugar, 1% by weight of flavor, 2% by weight of water, and 0.1% by weight of seaweed extract of any one or more of Examples <1-1> to <1-26> To prepare chewing gum.
<2-4> 캔디<2-4> candy
설탕 60 중량%, 물엿 39.8 중량% 및 향료 0.1 중량%와 상기 실시예 <1-1> 내지 <1-26> 중 어느 하나 이상의 해조류 추출물 0.1 중량%를 배합하여 통상의 방법으로 캔디를 제조하였다.Sugar 60% by weight, starch syrup 39.8% by weight, and 0.1% by weight of flavor, and 0.1% by weight of seaweed extract of any one of Examples <1-1> to <1-26> were mixed to prepare a candy by a conventional method.
<2-5> 비스켓<2-5> biscuit
박력 1급 25.59 중량%, 중력 1급 22.22 중량%, 정백당 4.80 중량%, 식염 0.73 중량%, 포도당 0.78 중량%, 팜쇼트닝 11.78 중량%, 암모늄 1.54 중량%, 중조 0.17 중량%, 중아황산나트륨 0.16 중량%, 쌀가루 1.45 중량%, 비타민 B 0.0001 중량%, 밀크향 0.04 중량%, 물 20.6998 중량%, 전지분유 1.16 중량%, 대용분유 0.29 중량%, 제1인산칼슘 0.03 중량%, 살포염 0.29 중량% 및 분무유 7.27 중량%와 상기 실시예 <1-1> 내지 <1-26> 중 어느 하나 이상의 해조류 추출물 0.1 중량%를 배합하여 통상의 방법으로 비스켓을 제조하였다.
[제조예 3] 화장품[Production Example 3] Cosmetics
<3-1> 영양화장수(밀크로션)<3-1> Nutritional lotion (milk lotion)
상기 실시예 <1-1> 내지 <1-26> 중 어느 하나 이상의 해조류 추출물을 하기 표 6의 영양화장수 제형 비율대로 하여 통상적인 방법에 따라 영양화장수를 제조하였다.Nutrient cosmetic water was prepared according to a conventional method by using any one or more seaweed extracts of Examples <1-1> to <1-26> according to the nutritional cosmetic water formulation ratio in Table 6 below.
(중량%)Manufacturing Example 3-1
(weight%)
어느 하나 이상의 해조류 추출물Among the above Examples <1-1> to <1-26>
Any one or more seaweed extracts
<3-2> 유연화장수(스킨로션)<3-2> Flexible lotion (skin lotion)
상기 실시예 <1-1> 내지 <1-26> 중 어느 하나 이상의 해조류 추출물을 하기 표 5의 유연화장수 제형 비율대로 하여 통상적인 방법에 따라 유연화장수를 제조하였다.In the above Examples <1-1> to <1-26> of any one or more seaweed extracts according to the ratio of the softening lotion formulation in Table 5 to prepare a flexible lotion according to a conventional method.
(중량%)Manufacturing Example 3-2
(weight%)
어느 하나 이상의 해조류 추출물Among the above Examples <1-1> to <1-26>
Any one or more seaweed extracts
<3-3> 영양크림<3-3> Nutrition cream
상기 실시예 <1-1> 내지 <1-26> 중 어느 하나 이상의 해조류 추출물을 하기 표 6의 영양크림 제형 비율대로 하여 통상적인 방법에 따라 영양크림을 제조하였다.A nutrient cream was prepared according to a conventional method by using at least one seaweed extract of Examples <1-1> to <1-26> according to the nutritional cream formulation ratio in Table 6 below.
(중량%)Manufacturing Example 3-3
(weight%)
어느 하나 이상의 해조류 추출물Among the above Examples <1-1> to <1-26>
Any one or more seaweed extracts
<3-4> 마사지크림<3-4> Massage cream
상기 실시예 <1-1> 내지 <1-26> 중 어느 하나 이상의 해조류 추출물을 하기 표 7의 마사지크림 제형 비율대로 하여 통상적인 방법에 따라 마사지크림을 제조하였다.A massage cream was prepared according to a conventional method by using at least one seaweed extract of Examples <1-1> to <1-26> according to the ratio of the massage cream formulation shown in Table 7 below.
(중량%)Manufacturing Example 3-4
(weight%)
어느 하나 이상의 해조류 추출물Among the above Examples <1-1> to <1-26>
Any one or more seaweed extracts
<3-5> 팩<3-5> pack
상기 실시예 <1-1> 내지 <1-26> 중 어느 하나 이상의 해조류 추출물을 하기 표 8의 팩 제형 비율대로 하여 통상적인 방법에 따라 팩을 제조하였다.A pack was prepared according to a conventional method by using at least one seaweed extract of Examples <1-1> to <1-26> according to the pack formulation ratio shown in Table 8 below.
(중량%)Manufacturing Example 3-5
(weight%)
어느 하나 이상의 해조류 추출물Among the above Examples <1-1> to <1-26>
Any one or more seaweed extracts
<3-6> 젤<3-6> gel
상기 실시예 <1-1> 내지 <1-26> 중 어느 하나 이상의 해조류 추출물을 하기 표 9의 젤 제형 비율대로 하여 통상적인 방법에 따라 젤을 제조하였다.A gel was prepared according to a conventional method by using at least one seaweed extract of Examples <1-1> to <1-26> according to the gel formulation ratio in Table 9 below.
(중량%)Manufacturing Example 3-6
(weight%)
어느 하나 이상의 해조류 추출물Among the above Examples <1-1> to <1-26>
Any one or more seaweed extracts
이상 살펴본 바와 같이, 본 발명은 해조류 추출물을 함유하는 근육 질환 예방 또는 치료용, 또는 근 기능 개선용 조성물을 제공한다. 보다 상세하게는 본 발명의 해조류 추출물은 근 단백질 합성에 관여하는 p-mTOR의 단백질 발현 증가, 근 단백질 분해에 관여하는 MuRF-1과 atrogin-1의 mRNA 발현을 억제하여 근육 질환 예방 또는 치료, 또는 근 기능 개선에 우수한 효과를 보인다. 본 발명의 다양한 해조류 추출물은 또한, 천연물이므로 부작용 없이 인체에 안전하게 사용될 수 있으며, 근육 질환 예방 또는 치료, 또는 근 기능 개선에 탁월한 효과를 보이는 조성물을 제공할 수 있으므로 산업상 이용가능성이 높다.As described above, the present invention provides a composition for preventing or treating muscle disease, or for improving muscle function, containing seaweed extract. More specifically, the seaweed extract of the present invention increases the protein expression of p-mTOR involved in muscle protein synthesis, inhibits the mRNA expression of MuRF-1 and atrogin-1 involved in muscle protein degradation to prevent or treat muscle diseases, or It has an excellent effect on improving muscle function. In addition, since various seaweed extracts of the present invention are natural products, they can be safely used in the human body without side effects, and because they can provide a composition exhibiting excellent effects in preventing or treating muscle diseases, or improving muscle function, it has high industrial applicability.
Claims (18)
A pharmaceutical composition for preventing or treating muscle diseases containing algae extract as an active ingredient.
The method according to claim 1, wherein the seaweed extract is a sprouting hatch ( Sargassum horneri ), a sawtooth hatch ( Sargassum serratifolium ), a scabbard hatch ( Sargassum sagamianum ), Sargassum confusum , a pretzel hatch ( Sargassum siliquastrum ), ( Sargassum thunbergii ), Codium fragile , Ulva pertusa , Codium contractum , Scytosiphon lomentaria , Ecklonia stolonifera , Costaria costata , Eisenia bicyclis , Undaria peterseniani , Ishige sinicola , Gloiopeltis tenax , Gloiopeltis furcata , Grateloupia elliptica , Gracilaria textorii , Chondracanthus tenellus One or more selected from the group consisting of ( Gracilaria verrucosa ), Gracilaria incurvata , Hypnea japonica , Gracilaria bursa-pastoris , Callophylis japonica , and Zostera marina . Pharmaceutical composition, characterized in that the extract.
The pharmaceutical composition according to claim 1, wherein the seaweed extract is obtained by extracting seaweed with at least one solvent selected from the group consisting of water, an organic solvent having 1 to 6 carbon atoms, a subcritical fluid, and a supercritical fluid.
The method of claim 3, wherein the organic solvent having 1 to 6 carbon atoms is an alcohol having 1 to 6 carbon atoms, acetone, ether, benzene, chloroform, and ethyl acetate. ), methylene chloride, hexane, cyclohexane, and petroleum ether. A pharmaceutical composition, characterized in that it is at least one solvent selected from the group consisting of.
The pharmaceutical composition according to claim 1, wherein the seaweed extract is obtained by extracting seaweed under ultra-high pressure conditions of 100 MPa or more.
The method of claim 1, wherein the muscle disease is selected from the group consisting of atony, muscular atrophy, muscular dystrophy, muscle degeneration, myasthenia, cachexia, and sarcopenia. Pharmaceutical composition, characterized in that at least one disease.
Food composition for preventing muscle disease or improving muscle function, containing algae extract as an active ingredient.
The method according to claim 7, wherein the seaweed extract is a sprouting hatch ( Sargassum horneri ), a sawtooth hatch ( Sargassum serratifolium ), a scabbard hatch ( Sargassum sagamianum ), Sargassum confusum , pretzel hatch ( Sargassum siliquastrum ), ( Sargassum thunbergii ), Codium fragile , Ulva pertusa , Codium contractum , Scytosiphon lomentaria , Ecklonia stolonifera , Costaria costata , Eisenia bicyclis , Undaria peterseniani , Ishige sinicola , Gloiopeltis tenax , Gloiopeltis furcata , Grateloupia elliptica , Gracilaria textorii , Chondracanthus tenellus One or more selected from the group consisting of ( Gracilaria verrucosa ), Gracilaria incurvata , Hypnea japonica , Gracilaria bursa-pastoris , Callophylis japonica , and Zostera marina . Food composition, characterized in that the extract.
The food composition according to claim 7, wherein the seaweed extract is obtained by extracting seaweed with at least one solvent selected from the group consisting of water, an organic solvent having 1 to 6 carbon atoms, a subcritical fluid, and a supercritical fluid.
The method of claim 9, wherein the organic solvent having 1 to 6 carbon atoms is an alcohol having 1 to 6 carbon atoms, acetone, ether, benzene, chloroform, ethyl acetate ), methylene chloride, hexane, cyclohexane, and petroleum ether. Food composition, characterized in that at least one solvent selected from the group consisting of.
The food composition according to claim 7, wherein the seaweed extract is obtained by extracting seaweed under ultra-high pressure conditions of 100 MPa or more.
The method of claim 7, wherein the muscle disease is selected from the group consisting of atony, muscular atrophy, muscular dystrophy, muscle degeneration, myasthenia, cachexia, and sarcopenia. Food composition, characterized in that at least one disease.
Cosmetic composition for improving muscle function containing algae extract as an active ingredient.
The method of claim 13, wherein the seaweed extract is Sargassum horneri , Sargassum serratifolium , Sargassum sagamianum , Sargassum confusum , pretzel, Sargassum siliquastrum , ( Sargassum thunbergii ), Codium fragile , Ulva pertusa , Codium contractum , Scytosiphon lomentaria , Ecklonia stolonifera , Costaria costata , Eisenia bicyclis , Undaria peterseniani , Ishige sinicola , Gloiopeltis tenax , Gloiopeltis furcata , Grateloupia elliptica , Gracilaria textorii , Chondracanthus tenellus One or more selected from the group consisting of ( Gracilaria verrucosa ), Gracilaria incurvata , Hypnea japonica , Gracilaria bursa-pastoris , Callophylis japonica , and Zostera marina . Cosmetic composition, characterized in that the extract.
14. The cosmetic composition of claim 13, wherein the seaweed extract is obtained by extracting seaweed with at least one solvent selected from the group consisting of water, an organic solvent having 1 to 6 carbon atoms, a subcritical fluid, and a supercritical fluid.
The method of claim 15, wherein the organic solvent having 1 to 6 carbon atoms is an alcohol having 1 to 6 carbon atoms, acetone, ether, benzene, chloroform, ethyl acetate ), methylene chloride, hexane, cyclohexane, and petroleum ether. A cosmetic composition, characterized in that it is at least one solvent selected from the group consisting of.
The cosmetic composition according to claim 13, wherein the seaweed extract is obtained by extracting seaweed under ultra-high pressure conditions of 100 MPa or more.
The method of claim 13, wherein the muscle disease is selected from the group consisting of atony, muscular atrophy, muscular dystrophy, muscle degeneration, myasthenia, cachexia, and sarcopenia. Cosmetic composition, characterized in that at least one disease.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190091417A KR20210014231A (en) | 2019-07-29 | 2019-07-29 | Composition for prevention or treatment of muscular disorders or improvement of muscular functions comprising seaweeds extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190091417A KR20210014231A (en) | 2019-07-29 | 2019-07-29 | Composition for prevention or treatment of muscular disorders or improvement of muscular functions comprising seaweeds extract |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20210014231A true KR20210014231A (en) | 2021-02-09 |
Family
ID=74559395
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020190091417A KR20210014231A (en) | 2019-07-29 | 2019-07-29 | Composition for prevention or treatment of muscular disorders or improvement of muscular functions comprising seaweeds extract |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20210014231A (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102296975B1 (en) * | 2021-04-28 | 2021-08-31 | 제주대학교 산학협력단 | Compostion for Improving Sarcopenia Using an Extract of Ishige okamurae or Diphlorethohydroxycarmalol |
KR102317113B1 (en) * | 2021-04-28 | 2021-10-22 | 제주대학교 산학협력단 | Compostion for Improving Muscle Strength or Muscular Atrophy Using an Extract of Ishige okamurae or Diphlorethohydroxycarmalol |
KR20220132921A (en) * | 2021-03-24 | 2022-10-04 | 화성용 | Pharmaceutical composition for preventing or treating sarcopenia comprising ENA as active ingredient |
WO2022244913A1 (en) * | 2021-05-20 | 2022-11-24 | 아쿠아그린텍(주) | Pharmaceutical composition for preventing or treating age-related sarcopenia containing ecklonia cava extract as active ingredient |
WO2023096345A1 (en) * | 2021-11-23 | 2023-06-01 | 부경대학교 산학협력단 | Composition for preventing or treating muscle disease comprising sargassum serratifolium extract |
-
2019
- 2019-07-29 KR KR1020190091417A patent/KR20210014231A/en unknown
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220132921A (en) * | 2021-03-24 | 2022-10-04 | 화성용 | Pharmaceutical composition for preventing or treating sarcopenia comprising ENA as active ingredient |
KR102296975B1 (en) * | 2021-04-28 | 2021-08-31 | 제주대학교 산학협력단 | Compostion for Improving Sarcopenia Using an Extract of Ishige okamurae or Diphlorethohydroxycarmalol |
KR102317113B1 (en) * | 2021-04-28 | 2021-10-22 | 제주대학교 산학협력단 | Compostion for Improving Muscle Strength or Muscular Atrophy Using an Extract of Ishige okamurae or Diphlorethohydroxycarmalol |
WO2022244913A1 (en) * | 2021-05-20 | 2022-11-24 | 아쿠아그린텍(주) | Pharmaceutical composition for preventing or treating age-related sarcopenia containing ecklonia cava extract as active ingredient |
WO2023096345A1 (en) * | 2021-11-23 | 2023-06-01 | 부경대학교 산학협력단 | Composition for preventing or treating muscle disease comprising sargassum serratifolium extract |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101982326B1 (en) | Composition for prevention, improvement or treatment of muscular disorder or improvement of muscular functions | |
US10960040B2 (en) | Composition for preventing and treating muscle diseases or improving muscular function, containing platycodon grandiflorum extract | |
US10576057B2 (en) | Methods for treating muscle wasting and degeneration diseases | |
KR20210014231A (en) | Composition for prevention or treatment of muscular disorders or improvement of muscular functions comprising seaweeds extract | |
JP6474418B2 (en) | Skin whitening or skin moisturizing composition containing fucosterol | |
KR101768806B1 (en) | Composition comprising a fermented Araliaceae plant for anti-inflammation or anti-cancer | |
KR101997060B1 (en) | Composition for prevention or treatment of muscular disorder, or improvement of muscular functions comprising fermented deer antler | |
KR102124986B1 (en) | Composition for prevention or treatment of muscular disorder or improvement of muscular functions comprising Leonurus japonicus extract or leonurine | |
KR101088069B1 (en) | Novel use of Panduratin derivatives or extract of Kaempferia pandurata comprising the same | |
US11622984B2 (en) | Composition comprising aster sphathulifolius maxim extract for preventing, improving, or treating muscular diseases or for improving muscular functions | |
KR102167958B1 (en) | Composition for prevention and treatment of muscular disorders or improvement of muscular functions comprising extract of Amaranthus spp. or grain cereals | |
KR101809379B1 (en) | Composition comprising Diosmin or as active ingredients for Preventing or treating muscle disease | |
KR20200140749A (en) | Composition for improvement, treatment or prevention of muscular disorders, or improvement of muscular functions comprising Cudrania tricuspidata | |
KR102158134B1 (en) | Antibacterial composition comprising an extract of schisandra chinesis | |
KR101757841B1 (en) | Composition for inhibiting obesity comprising complex salt of baicalin and zinc | |
KR20070113330A (en) | A composition containing ecklonia stolonifera extract for skin external application | |
KR101830395B1 (en) | Composition comprising squalene for enhancement of muscle function and prevention of muscle damage | |
KR102217264B1 (en) | Composition for Preventing, Improving or Treating of muscular disease containing Codium SPP. algae extract | |
KR20150113709A (en) | Skin whitening composition containing Allium hookeri extract | |
KR20200083146A (en) | Composition for prevention and treatment of muscular disorder or improvement of muscular functions comprising Illicium verum extract or shikimic acid | |
KR102352636B1 (en) | Composition for prevention and treatment of muscular disorder or improvement of muscular functions comprising Illicium verum extract or shikimic acid | |
KR102633488B1 (en) | Composition for improvement, prevention or treatment of muscular disorders, or improvement of muscular functions comprising Korean mint extract or tilianin | |
KR102517662B1 (en) | Composition for improvement, treatment or prevention of muscular disorders, or improvement of muscular functions comprising chaga | |
KR102104518B1 (en) | Antifungal composition comprising an extract of jujube leaves, or mixed extract of jujube leaves and Acanthopanax senticosus | |
KR20200123688A (en) | Composition for prevention and treatment of muscular disorder or improvement of muscular functions comprising Artemisia argyi extract |